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ABSTRACT 
The mammalian gut evolved to foster the development and maintenance of a community of 
specific bacterial symbionts that persist for years. Bacteroides fragilis is one of a number of 
species that are able to colonize the mucus of the large intestine in mice and humans. This 
thesis explores the mechanisms and functions of mucosal colonization, most notably by using 
reductionist approaches with gnotobiotic mice. Harnessing genetics on both the host and 
microbial side allowed the dissection of a pathway by which immunoglobulin A enhances 
mucosal colonization by B. fragilis. Novel colonization assays were developed to explore the 
importance of mucosal colonization to bacterial fitness. Finally, an enrichment method for 
host-associated bacterial transcriptomics was used to define the behavior of this symbiont 
within the mucus layer. 
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C h a p t e r  1  
GUT BIOGEOGRAPHY OF THE BACTERIAL MICROBIOTA 
 
Donaldson G.P., Lee S.M., and Mazmanian S.K. 
This chapter was published in 2016 in Nature Reviews Microbiology 14 (1): 20-32. DOI: 
10.1038/nmicro3552 
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PREFACE 
Animals assemble and maintain a diverse yet host-specific gut microbial community. In 
addition to characteristic microbial compositions along the longitudinal axis of the intestines, 
discrete bacterial communities form in microhabitats, such as the gut lumen, colon mucus 
layers, and colon crypts. In this review, we examine how spatial distribution of symbiotic 
bacteria among physical niches in the gut impacts the development and maintenance of a 
resilient microbial ecosystem. We consider novel hypotheses for how nutrient selection, 
immune activation, and other mechanisms control the biogeography of bacteria in the gut 
and discuss the relevance of this spatial heterogeneity to health and disease.  
 3 
INTRODUCTION 
Humans and other mammals harbor a complex gastrointestinal microbiota, which includes 
all three domains of life (Archaea, Bacteria and Eukaryota). This extraordinary symbiosis, 
formed via a series of exposures to environmental factors, is initiated upon contact with the 
vaginal microbiota during birth1. Abrupt changes during the first year of life follow a pattern 
that corresponds to gestational age in both mice2 and humans3, which suggests that strong 
deterministic processes shape the composition of the microbiota during development. These 
population shifts may be explained by influences from diet, the developing immune system, 
and chemical exposures, as well as potential founder effects of initial colonizers. Founder 
effects are not well understood in the mammalian gut, but the profound changes in host gene 
expression that occur in response to microorganisms, and the great potential for syntrophic 
interactions between bacteria suggest that early colonizers may have long-term effects on the 
establishment of the microbiota. The immune system imposes selective pressure on the 
microbiota through both innate and adaptive mechanisms such as antimicrobial peptides4, 
secreted immunoglobulin A (IgA)5, and other contributing factors6 (see below). However, 
current research suggests that diet may have the greatest impact on microbiota assembly. 
Prior to weaning, breast milk plays a crucial part in shaping the microbial community 
composition via transmission of the milk microbiota to the infant gut7, protection from 
harmful species by secreted maternal antibodies8, and selection for certain species by milk 
oligosaccharides, which can be used by microorganisms as carbon sources9. For example, in 
in vitro competitive growth experiments, Bifidobacterium longum benefits from its ability to 
use fucosylated oligosaccharides that are present in human milk to outgrow other bacteria 
that are usually present in the gut microbiota, such as Escherichia coli and Clostridium 
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perfringens10. Several species of Bacteroides can also utilize fucosylated oligosaccharides as 
carbon sources11, suggesting that their colonization may be aided by prebiotic properties of 
milk. Accordingly, children of mothers with nonfunctional fucosyltransferase 2, an enzyme 
required for fucosylation of milk oligosaccharides, display lower levels of fecal 
Bifidobacteria and Bacteroides species12. The importance of diet in determining the 
composition of the microbial community in the gut is also highlighted by the observation 
that transition to solid foods coincides with establishment of an adult-like microbiota. 
 
The adult intestinal microbiota consists of hundreds to thousands of species, dominated by 
the Bacteroidetes and Firmicutes phyla13. This ecosystem is distinct from that of any other 
microbial habitats that have been surveyed14, and includes many species that exist nowhere 
else in nature, indicating that coevolution of the host with its gut microbial symbionts 
(including commensals and mutualists) has generated powerful selective mechanisms. A 
recent study of how different microbial communities colonize gnotobiotic animals showed 
that deterministic mechanisms (presumably host-microorganism interactions) led to 
reproducible shaping of the microbiota regardless of the source of the input community15.  
 
The adult intestinal microbiota is also partially stable, as a core of ~40 bacterial species 
(accounting for 75% of the gut microbiota in terms of abundance) persists for at least a year 
in individuals16. A more extensive longitudinal study found that 60% of all bacterial strains 
within an individual persisted for five years17. During severe perturbations such as antibiotic 
treatment, the fecal community is depleted to a low-diversity consortium, but after a recovery 
period membership and relative abundance largely resemble the pretreatment state18. Some 
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species that are depleted to undetectable levels in stool are later recovered18, suggesting that 
there may be reservoirs of bacterial cells that can re-seed the intestinal lumen.  
 
The mucus layer, crypts of the colon, and appendix are examples of privileged anatomical 
sites, protected from the fecal stream and accessible only to certain microorganisms. In this 
review, we highlight relevant features of spatial heterogeneity of bacterial species and 
communities in the gut microbiota, and discuss the impact of microbial localization in 
engendering specific and stable colonization with profound implications for health and 
disease. 
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MICROBIAL COMPOSITION OF THE GUT 
The mammalian lower gastrointestinal tract contains a variety of distinct microbial habitats 
along the small intestine, cecum, and large intestine (colon). Physiological variation along 
the lengths of the small intestine and colon include chemical and nutrient gradients, as well 
as compartmentalized host immune activity, which are known to influence bacterial 
community composition. For example, the small intestine is more acidic, and has higher 
levels of oxygen and antimicrobials than the colon (Figure 1A). Therefore, the small intestine 
microbial community is dominated by fast-growing facultative anaerobes that tolerate the 
combined effects of bile acids and antimicrobials, while still effectively competing for simple 
carbohydrates that are available in this region of the gastrointestinal tract. Bile acids, secreted 
through the bile duct at the proximal end of the small intestine, are bactericidal to certain 
species due to their surfactant properties and are known to broadly shape the composition of 
the microbiota, especially in the small intestine. For example, feeding mice excess bile acids 
generally stimulates the growth of Firmicutes and inhibits Bacteroidetes19. Additionally, the 
shorter transit time in the small intestine compared to colon (an order of magnitude shorter, 
despite the increased length of the small intestine) is thought to make bacterial adherence to 
tissue or mucus an important factor for persistent colonization of the small intestine. 
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Figure 1: Microbial habitats in the human lower gastrointestinal tract. The dominant 
bacterial phyla in the gut are the Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria, 
and  Verrucomicrobia. A) The dominant bacterial families of the small intestine and colon 
reflect physiological differences along the length of the gut. For example, a gradient of 
oxygen, antimicrobial peptides (including bile acids, secreted by the bile duct), and pH limits 
the bacterial density in the small intestinal community, whereas the colon carries high 
bacterial loads. In the small intestine, Lactobacillaceae and Enterobacteriaceae dominate, 
whereas the colon is characterized by the presence of Bacteroidaceae, Prevotellaceae, 
Rikenellaceae, Lachnospiraceae, and Ruminococcaceae. B) A cross-section of the colon 
shows the digesta – which is dominated by Bacteroidaceae, Prevotellaceae and Rikenellaceae 
– and the inter-fold regions of the lumen – which are dominated by Lachnospiraceae and 
Ruminococcaceae. 
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In ileostomy samples from humans, the small intestine was found to exhibit lower bacterial 
diversity than the colon, and was highly enriched in certain Proteobacteria and Clostridium 
species20. Furthermore, a metatranscriptomic analysis revealed that the expression of genes 
involved in central metabolism and in pathways responsible for import of simple sugars by 
facultative anaerobes was greatly enriched in ileal samples, compared to fecal samples20. In 
mice, Lactobacillaceae and Proteobacteria (especially Enterobacteriaceae) are enriched in 
the small intestine21 (Figure 1A). Although bacteria in the small intestine are potentially 
competing with the host for nutrients, host-derived bile acids and antimicrobial peptides limit 
bacterial growth to low densities in proximal regions. Only at the distal end of the small 
intestine (in the terminal ileum) do bacterial densities reach saturating levels similar to those 
found in the large intestine (Figure 1A). 
 
The cecum and colon cultivate the most dense and diverse communities of all body habitats. 
Mice, like most herbivorous mammals, have a large cecum between the small and large 
intestine where plant fibers are slowly digested by the microbiota. Humans have a small 
pouch-like cecum with an attached appendix, a thin tube-like extension (Figure 1A). In the 
cecum and colon, microorganisms are responsible for the breakdown of otherwise ‘resistant’ 
polysaccharides that are not metabolized during transit through the small intestine. Lower 
concentrations of antimicrobials, slower transit time, and a lack of available simple carbon 
sources facilitate the growth of fermentative polysaccharide-degrading anaerobes, notably 
those of the high-abundance families Bacteroidaceae and Clostridiaceae. In the mouse, the 
cecum is enriched in Ruminococcaceae and Lachnospiraceae, while the colon is enriched in 
Bacteroidaceae and Prevotellaceae21. Rikenellaceae are prominent in both the cecum and 
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colon21. Various host factors drive community differences over the cross-sectional axis of 
the gut. The entire wall of the colon folds over itself, creating compartments between folds 
(inter-fold regions) that are distinct from the central lumenal compartment (Figure 1B). In 
mouse studies that used laser capture microdissection to profile the composition of the 
microbial communities in discrete regions, significant differences were observed between 
the central lumen compartment and the inter-fold region22,23. Specifically, the Firmicutes 
families Lachnospiraceae and Ruminococcaceae were enriched between folds while the 
Bacteroidetes families Prevotellaceae, Bacteroidaceae, and Rikenellaceae were enriched in 
the digesta22. Relative to the digesta, the inter-fold regions are likely to contain greater 
amounts of mucus, which can serve as a nutrient source for certain bacteria. 
 
Gut microhabitats: mucus and colon crypts 
Throughout the human small intestine and colon, specialized epithelial cells called goblet 
cells secrete a mucus layer of varying thickness that partially or fully covers the epithelium 
depending on the region, creating a boundary between the gut lumen and host tissue (Figure 
2A and 2B). The small intestine harbors a single, tightly-attached mucus layer (Figure 2A), 
whereas in the colon, mucus is organized into two distinct layers: an outer, loose layer, and 
an inner, denser layer that is firmly attached to the epithelium (Figure 2B). As mentioned 
above, bacterial densities are much higher in the colon, compared to the small intestine, and 
examination of the colon by fluorescence in situ hybridization (FISH) has shown that the 
inner mucus layer appears essentially sterile next to the densely populated outer layer24. In 
addition to mucus density itself serving as a physical obstacle for microorganisms, 
antimicrobial molecules and oxygen secreted from the epithelium accumulate higher local 
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concentrations within the mucosa, especially in the small intestine, greatly restricting 
potential microbial inhabitants. 
 
Figure 2: The mucus layers of the small intestine and colon. Several factors limit the ability 
of gut bacteria to access host cells, including the mucus layers in the small intestine and the 
colon; antimicrobial peptides in the small intestine, including those produced by Paneth cells 
at the base of the crypts; secreted immunoglobulin A (sIgA) in both the small intestine and 
colon; and a steep oxygen gradient that influences which bacteria are capable of surviving 
close to the epithelial surface. A) The surface of the small intestine is shaped into villi and 
crypts and is colonized by certain adherent species, including segmented filamentous bacteria 
(SFB), Lactobacillaceae and Helicobacter spp. B) The colon has two distinct mucus 
structures: the outer layer is colonized by mucin-degrading bacteria and is characterized by 
the presence of Bacteroides acidifaciens, Bacteroides fragilis, Bifidobacteriaceae, and 
Akkermansia muciniphila and the inner layer and crypts are penetrated at low density by a 
more restricted community that includes Bacteroides fragilis and Acinetobacter spp. 
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Mucus is continuously secreted and the outer layers are sloughed off, generating ‘islands’ of 
mucus that are carried into the fecal stream25. In mice, a viscosity gradient of the gel-forming 
mucus increases from the proximal colon (which includes the cecum and the ascending and 
transverse colon) to distal colonic sites (which includes the descending colon and the sigmoid 
colon that connects to the rectum). Accordingly, there are more mucus-associated bacteria in 
the proximal region26. Mucosal biofilm formation in the proximal colon is conserved from 
mammals to amphibians27, suggesting an ancient, evolutionarily conserved origin of this 
region for interactions with bacteria. Therefore, the mucus layers of the gastrointestinal tract 
create environments that are distinct, protected habitats for specific bacterial ecosystems that 
thrive in proximity to host tissue. 
 
Divergence between the mucosal and lumenal (digesta-associated) colonic communities has 
been observed in several mammals including humans28, macaques29, mice30, cows31, and 
flying squirrels32. More specifically, human colon biopsy and swab samples have revealed a 
distinct mucosal community enriched in Actinobacteria and Proteobacteria compared to the 
lumen community33. Certain species are highly enriched in colon mucus, such as the mucin-
degraders Bacteroides acidifaciens in mice34, Bacteroides fragilis in macaques29, and 
Akkermansia muciniphila in mice and humans34,35 (Figure 2B). Human mucosal 
communities in biopsy36-38 and lavage39 samples of the colon contain significant variability 
between sample locations less than one centimeter apart, suggestive of the existence of 
mucosal microbial populations in patches. Interestingly, an imaging study using approaches 
that carefully preserve the structure of feces also identified discrete patches; individual 
groups of bacteria were found to spatially vary in abundance from undetectable to saturating 
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levels25. This spatial niche partitioning in feces may be reflective of aggregates of interacting 
microorganisms, heterogeneity of nutrient availability in plant fibers, or microenvironments 
in mucosally-associated communities that imprint the digesta as it transits through the gut. 
Therefore, microbial profiling of fecal samples, which is the most common strategy 
employed in microbiome studies, represents an incomplete and skewed view of even the 
colon, which has distinct mucosal communities and spatial heterogeneity that is lost upon 
sample homogenization. 
Some bacteria completely penetrate the mucus and are able to associate directly with 
the epithelium, within the crypts of the colon. Crypt-associated microorganisms were first 
described using electron microscopy40,41. Many subsequent imaging studies likely failed to 
observe or underestimated the number of tissue-associated bacteria because common 
washing and fixing methods can remove mucosal biofilms42. This led to the hypothesis that 
the mucosal surface is largely devoid of microbial colonization in healthy individuals. 
However, imaging studies using Carnoy’s fixative, which is known to preserve the mucosal 
layer, found that there are bacteria in a significant fraction of colonic crypts in healthy mice43 
and humans44. More recent work using laser microdissection and sequencing to profile 
mouse crypt-associated communities revealed that the community is especially dominated 
by Acinetobacter spp. and is generally enriched for Proteobacteria capable of aerobic 
metabolism23 (Figure 2B). Evasion of immune responses and particular metabolic activities 
are likely required for crypt occupancy by microorganisms specialized to reside in close 
proximity to the host. A well-characterized example of this adaptation is the ability of the 
human symbiont B. fragilis to enter crypts of the proximal colon of mice via a process 
requiring both modulation of the immune system45 and utilization of specific host-derived 
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nutrients46 (see below). While dogma has emerged that microorganisms contact mucosal 
surfaces exclusively in disease states, it appears that life-long physical associations between 
specific members of the microbiota and their hosts represent symbioses forged over millennia 
of co-evolution.  
 
  
 14 
MECHANISMS RESPONSIBLE FOR GUT BIOGEOGRAPHY 
Several factors influence the biogeography of bacteria within the gut, including diet, 
antimicrobials, mucus and adherence, and the host immune system. 
 
Diet and nutrients 
Bacterial metabolism in the gut likely contributes to the localization of particular groups of 
microorganisms. Because fatty acids and simple carbohydrates from food are absorbed and 
depleted during transit through the small intestine, sustainability of the colonic bacterial 
ecosystem requires growth by fermentation of complex polysaccharides, the principal carbon 
sources that reach the colon. Best studied in this regard are Bacteroides species, which are 
able to catabolize polysaccharides derived from the diet and from the host47. Compared to 
other gut bacteria, Bacteroides have the largest number and diversity of genes involved in 
polysaccharide degradation48. This extensive array of polysaccharide utilization systems is 
dominated by those resembling the starch utilization system (Sus), originally described in 
Bacteroides thetaiotaomicron 49. Sus systems consist of lipid-anchored enzymes either 
secreted or displayed on the bacterial cell surface that can catabolize particular complex 
glycans into smaller oligosaccharides, which are then imported through a dedicated outer 
membrane transporter (Figure 3A). In the gut, Bacteroides species use Sus-like systems to 
break down dietary polysaccharides and host-derived mucin glycans50. The genome of B. 
thetaiotaomicron encodes 88 Sus-like systems presumably with different glycan 
specificities, providing remarkable metabolic flexibility51. Based on these findings, 
Bacteroides species, and B. thetaiotaomicron in particular, are sometimes referred to as 
“generalists,” capable of occupying a variety of metabolic niches depending on the 
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availability of diverse polysaccharide nutrients. 
 
Figure 3: Bacterial colonization determinants. Several factors affect the localization of 
bacteria within the gastrointestinal tract, including the ability to utilize different glycans and 
to resist antimicrobial peptides (AMPs). A) Sus-like systems in Bacteroides species allow 
the utilization of complex polysaccharides from the diet or the host. The figure illustrates a 
generalized schematic of a Sus-like system. Homologues of SusD and other outer membrane 
lipid-anchored enzymes bind and cleave the glycans (such as starch) into smaller 
oligosaccharides that are then imported by the SusC-like outer membrane transporter. 
Interaction with the cognate glycan often leads to transmembrane signaling to activate gene 
regulatory mechanisms, such as a two-component system or a transmembrane anti-sigma 
factor which releases and activates a sigma factor. Downstream transcriptional regulation 
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allows Bacteroides species to respond to local availability of glycans. B) Cationic AMPs in 
the small intestine, which also pass into the colon via the fecal stream, disrupt bacterial outer 
membranes by interacting with negative charges on their surface. By removing phosphate 
groups from lipid A of lipopolysaccharide (LPS), pathogens and commensals alike–such as 
Helicobacter pylori, Salmonella spp., and various Firmicutes and Bacteroidetes–reduce the 
negative charge on their membranes and evade attack by cationic AMPs. 
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Diet-derived polysaccharides control microbial community composition in the lumen of the 
colon. Unsurprisingly, the influence of diet is readily apparent in studies that profile the fecal 
community. A study of humans that completely switched between plant and animal-based 
diets showed that the microbiome abruptly shifts with diet52. Over small time scales this 
effect is reversible, suggesting that these changes represent transient ecosystem adaptations 
via blooms of particular species in the lumen while the mucosal reservoir remains unchanged. 
Many studies of Bacteroides glycan metabolism have shown that restricting the 
polysaccharide content of the mouse diet allows selection for species (or strains) that are 
capable of metabolizing the complex glycans present, such as fructans53, human milk 
oligosaccharides11, fucosylated mucin glycans54, and mannan55. Presumably, the variety of 
Sus-like systems present in the genomes of Bacteroides provides the metabolic plasticity to 
persist in the gut despite short and long-term changes in nutrient availability. However, even 
in terms of monosaccharide and disaccharide utilization, there is a hierarchy of bacteria that 
are more efficient consumers, which helps explain how diet can dramatically and rapidly 
change the composition of the fecal community. Importantly, the nutrient environment of the 
gut lumen may be in a dynamic state of flux due to potential meal-to-meal variability, 
especially in omnivorous mammals. 
 
In contrast to the variable conditions in the gut lumen, mammals likely maintain a more 
consistent nutrient balance in the mucosa, which serves as a stable positive selection factor 
for certain species of bacteria. Mucus degradation and metabolism by gut microorganisms 
provides access to privileged spatial niches and therefore a competitive advantage over other 
species, both indigenous and invasive. For example, several studies have shown that the 
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ability to grow in an in vitro mucus culture is generally predictive of the ability of a bacterial 
species to colonize the mouse gut56,57. MUC2 alone is coated with over 100 different O-
linked glycan structures in humans58. These glycans differ between mice and humans59, and 
differences in complex glycan “preference” by various bacterial species are a suggested 
mechanism of host-specific selection of a characteristic microbiome profile. In agreement, 
computational models have shown that positive selection at the epithelium via the ability to 
metabolize  specific nutrients can be a more powerful mechanism for shaping host-associated 
microbial communities than negative selection driven by antimicrobials60.  
 
A. muciniphila, a prominent symbiont in many mammals, is one of the most effective mucin 
degraders in vitro35 and is consistently found at high abundance in the mucus layer in 
humans35 and mice34. Consumption of mucus glycans as a carbon and energy source allows 
A. muciniphila and other mucin-degraders to colonize the gut independently of the animal’s 
diet, providing a clear advantage to the bacteria during conditions of nutrient deprivation. 
Accordingly, levels of A. muciniphila increase in fasting Syrian hamsters61 and hibernating 
ground squirrels62. Similarly, during intestinal inflammation in mice, the community 
metatranscriptome indicates increased mucin utilization with a corresponding increase in 
abundance of the mucin-degrading B. acidifaciens63. In gnotobiotic mice, restriction of 
complex polysaccharides in the diet causes the generalist B. thetaiotaomicron to shift its 
metabolism to utilize mucin glycans50. Further work has revealed that mutations in Sus-like 
systems involved in mucin glycan utilization in B. thetaiotaomicron cause a defect in 
competitive colonization and in vertical transmission of bacteria from mother to pup64. 
Therefore, the ability to utilize mucus as a carbon and energy source contributes to the ability 
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of some microorganisms to stably colonize the host and transfer to offspring across 
generations. Not surprisingly, genetic manipulation of enteric mucus production in mice 
changes microbial community composition54,65. In turn, gut bacteria affect transcription of 
mucin-encoding genes in mice66. Overall, development of a healthy mucosa is a 
collaborative, bi-directional event between the host and the gut microbiota, creating an 
environment that allows the specific members to establish persistent colonization via 
utilization of host-derived glycans.  
 
In some cases, the ability of a bacterium to colonize the gut may be determined by its ability 
to utilize a specific, yet limiting, nutrient. Bacterial species-specific carbohydrate utilization 
systems termed commensal colonization factors (CCFs) have been identified in B. fragilis 
and Bacteroides vulgatus, and allow these bacteria to colonize saturable nutrient niches46. 
This discovery was made based on the observation that gnotobiotic mice colonized with a 
specific Bacteroides species are resistant to colonization by the same species, but not 
colonization by closely related species. A genetic screen revealed that a set of genes encoding 
the CCF system was required for this intra-species colonization resistance phenotype (Box 
1), suggesting that CCFs are responsible for defining the species-specific niche. Accordingly, 
when the ccf genes from B. fragilis were expressed in B. vulgatus, the resulting hybrid strain 
gained the ability to colonize an alternate niche. The CCF system was also required for 
penetration of B. fragilis into the crypts of the colon and long-term resilience to intestinal 
perturbations such as antibiotic treatment and gastroenteritis. Collectively, these data suggest 
that while metabolic flexibility allows bacterial adaptation in the lumen environment, the 
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occupation of a narrowly-defined, tissue-associated niche is likely very important for stable 
colonization by some bacteria. 
 
Box 1: Colonization resistance.  
One of the benefits afforded by the microbiota to the host is colonization resistance to 
pathogens. Invasive species of bacteria are inhibited from colonizing the gut because they 
are unable to displace indigenous species that have gained a strong foothold. After years of 
studying colonization resistance against pathogens in gnotobiotic animals in the 1960’s and 
70’s, Rolf Freter theorized that the ability of a bacterial species to colonize the gut is 
determined by its ability to utilize a specific, limiting nutrient135. This notion has been well 
supported by studies showing that colonization resistance to pathogens is mediated by the 
availability of nutrient niches in the cases of Escherichia coli136 and Clostridium difficile137. 
But Freter’s hypothesis reached even further, suggesting that the relative amounts of limiting 
nutrients could dictate the abundance of each species in the indigenous community. 
Correspondingly, the variety of host-derived growth substrates could explain the stable 
diversity of the gut microbiota if individual species have evolved to specialize in the uptake 
and metabolism of specific, limiting nutrients, such as in the case of Bacteroides fragilis46. 
The concept of spatial niche partitioning being governed by host production of specific and 
scarce nutrient resources is attractive, and may help explain both long-term persistence and 
resilience of the microbiome, as well as colonization resistance to pathogens.  
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Antimicrobials 
Specialized epithelial immune cells called Paneth cells reside at the base of the crypts of the 
small intestine, secreting an array of antimicrobials that restrict the growth of bacteria that 
are found near the mucosal surface4. Many of these molecules are cationic antimicrobial 
peptides that interact with and disrupt negatively charged bacterial membranes (Figure 3B). 
Modifications to lipid A, a major component of the outer membrane of gram-negative 
bacteria, are known to confer resistance to cationic antimicrobial peptides in several 
pathogens67. Interestingly, underphosphorylation of this lipid portion of LPS, a modification 
shared with the pathobiont Helicobacter pylori, was found to be important for resilient 
colonization by B. thetaiotaomicron during inflammation68 (Figure 3B).  
 
The concentration of a variety of antimicrobials is higher toward the proximal end of the 
small intestine, creating a gradient that leads to a higher abundance and diversity of bacteria 
in distal locations (Figure 1A). For example, the lectin RegIII! is bactericidal to gram-
positive bacteria that dominate the small intestine because it binds to and disrupts their 
exposed peptidoglycan layer. RegIII! is required to prevent massive infiltration of the 
mucosa and microbial invasion of the tissue69. In addition to RegIII!, the innate immune 
system deploys many other antimicrobials (such as alpha-defensins from Paneth cells and 
beta-defensins from neutrophils) with differing specificities to limit access to the 
epithelium70, and resistance to these host-derived antimicrobial peptides is a general feature 
of many indigenous gut species of Firmicutes and Bacteroidetes68.  
 
In addition to these antimicrobials, gut bacteria, which are largely anaerobic, must contend 
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with reactive oxygen species produced by aerobic host metabolism. Rapid dilution and 
consumption of oxygen secreted from the host tissue generates a gradient of oxygen that 
decreases in concentration from tissue to lumen (Figure 2). Accordingly, the mucosal 
community is enriched in genes required for resistance to reactive oxygen species33. Notably, 
although all Bacteroides species are classified as obligate anaerobes, B. fragilis can use 
oxygen as a terminal electron acceptor at nanomolar concentrations71. B. fragilis and tissue-
associated, microaerophilic Lactobacillaceae express catalase, superoxide dismutase, and 
other enzymes to inactivate reactive oxygen species72. Altogether, these mechanisms restrict 
access to the epithelium to a subset of bacterial species that not only can utilize nutrients 
found only at the tissue boundary, but can survive host antimicrobial strategies as well. 
 
Mucus and adhesion 
To access the epithelium, pathogens and commensals alike must contend with the mucus 
barrier and the immune system (Figure 4). Secreted MUC2 forms peptide crosslinks to create 
a viscous gel-like substance73, serving as a barrier and host defense mechanism74. In mice 
lacking MUC2, the crypts of the colon are filled with bacteria and the tissue is covered in 
biofilms24, indicating that the gel-forming mucus is the primary barrier to tissue association 
by the microbiota at large. However, certain bacteria are able to penetrate the mucus by 
swimming or eating their way through.  
 
In the gut, bacterial motility is generally restricted due to the immunogenicity of flagellin, 
which is a ligand for Toll-like Receptor 5 (TLR5)75, and the viscosity of mucus limits the 
effectiveness of swimming (Figure 4). Still, the enteric pathogen Salmonella enterica 
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subspecies enterica serovar Typhimurium depends on flagella and chemotaxis to penetrate 
the mucus layer and to reach host tissue76. E. coli and close relative Shigella flexneri opt for 
an alternative strategy of secreting a mucin-binding serine protease, Pic, which rapidly 
digests mucus (Figure 4). Interestingly, Pic also causes hypersecretion of mucus, which may 
interfere with the ability of indigenous bacteria to compete with the pathogen77. Similarly, 
another family of mucus-degrading proteins, M60-like peptidases, are conserved in 
pathogens and commensal mucosal bacteria from the Proteobacteria, Firmicutes, 
Bacteroidetes, and other phyla78. In enterotoxigenic E. coli, an M60-like peptidase was 
required for association with villi in the mouse small intestine79. 
 
In addition to the ability to penetrate the mucus layer, bacterial adhesion to the epithelium 
also influences the microbial composition of the gut, especially in the small intestine (Figure 
2A). Species of Helicobacter adhere to and colonize the the stomach and small intestine 
tissue via adherence to epithelial surface glycans80. Further downstream in the small 
intestine, segmented filamentous bacteria (SFB) adhere intimately to the epithelial surface, 
as first described in imaging studies of mice81. Host-specific strains of SFB appear to be 
present in many mammals, including humans82. These bacteria were only recently cultured 
in vitro using tissue-cultured enterocytes as a platform to support their growth, reinforcing 
the idea that they are obligate symbionts with the mammalian gut tissue83. Their mechanism 
of attachment is still a mystery, though the attachment site is marked by accumulation of 
actin and leaves a visible indentation on the surface of the epithelial cell following removal 
of the filaments83. By virtue of intimate host association, SFB shape the host immune 
response84 and impact autoimmune disease in mouse models85,86.  
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Figure 4: Bacterial access to 
the epithelium. Both bacterial 
pathogens (red) and 
commensals (or mutualists; 
blue) have the ability to cross 
the mucus layer and access 
the gut epithelium. Lectins 
and other mucus-binding 
proteins facilitate initial 
interactions with the mucus 
layer. Mucinases and 
proteases are used to degrade 
mucus for bacteria to “eat” their way through, while some pathogens such as Salmonella spp. 
use flagella to swim through the viscous mucus. TLR5 sensing of flagellin effectively leads 
to inhibition of flagellar biosynthesis for most bacteria in the gut. Adherence to the tissue is 
achieved by both commensals and pathogens through pili, lectins, and other outer-membrane 
proteins that target ligands on the epithelial cell surface. Adherence facilitates gut 
colonization for both commensals and pathogens, and also allows tissue invasion by 
pathogenic bacteria. Microfold cells (M cells) are specialized immune sentinel epithelial cells 
that detect gut bacteria and are also exploited by many pathogens as a means of translocation 
across the epithelium. 
Pathogen
Commensal
mucus binding
membrane proteins
secreted mucinases
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The molecular mechanisms underlying how microorganisms attach to host tissue have been 
well-studied in pathogens87. Although all of these features were initially discovered and 
described in pathogens, they are found in many commensal bacteria. Bacteria adhere to 
mucus and epithelial surfaces by deploying outer membrane proteins, capsules, lectins, 
adhesins, and fimbriae (attachment pili) (Figure 4). For example, the non-invasive pathogen 
Vibrio cholerae forms a layer of adhered cells on the wall of the small intestine using toxin-
coregulated pili (TCP) 88. V. cholerae also binds mucins using an outer membrane N-acetyl-
D-glucosamine (GlcNAc)-binding protein, which may also facilitate penetration of the 
mucus and access to the epithelium89. Without attachment, these naturally plankton-
associated marine bacteria are unable to colonize the gut, and thus are avirulent. E. coli 
possesses a great number of lectins with diverse sugar specificities allowing it to bind mucins 
as well as other glycoproteins and extracellular matrix components of epithelial cells90. 
Invasive pathogens also depend on adherence factors as a preceding step to penetration and 
infection of the tissue. Listeria monocytogenes expresses a surface protein, internalin A, 
which binds epithelial E-cadherin (a host cell adhesion protein) as a first step before 
exploiting actin to induce phagocytosis91. Studies of S. Typhimurium also reveal a critical 
role of apical surface attachment in inducing neutrophil-mediated inflammation, which 
appears to paradoxically promote infection92 by providing a competitive advantage for the 
pathogen over the resident microbiota93. 
 
Beneficial microorganisms also adhere to particular regions of the epithelium and can serve 
to exclude adherent pathogens by occupying limited binding sites, although little is known 
about the underlying mechanisms or functions of this process (Box 1). Early imaging studies 
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revealed that Lactobacillus spp. that form adherent layers on the epithelium in the rat stomach 
prevent yeast94 and staphylococcal95 adherence to the epithelium. Members of the family 
Lactobacillaceae (such as Lactobacillus and Lactoccocus) that colonize the small intestine 
and stomach have become model systems for studying adhesion by commensals, with 
exopolysaccharides, pili, and cell wall-anchored proteins found to be involved in interacting 
with mucus, extracellular matrix proteins, and other molecular targets on the epithelial cell 
surface96. Notably, cell wall-anchored mucus-binding proteins (MUBs) unique to lactobacilli 
are known to be involved in both adherence and aggregation97. Strain-specific diversity in 
adherence and aggregation factors underlies the host specificity of Lactobacillis reuteri, 
indicating that tissue-associated biofilm formation is fundamental to colonization by this 
species98. Other means of attachment involve mechanisms conserved with pathogens, such 
as adhesive pili in Lactobacillus rhamnosus that bind mucus99. Analogous mechanisms can 
be found in unrelated species such as Bifidobacterium bifidum, which uses pili to bind 
extracellular matrix proteins, contributing to bacterial aggregation100.  
 
Collectively, these studies suggest that interactions with mucus and adherence to intestinal 
epithelial cells appear to be adaptations used by pathogens during infection, as well as 
strategies employed by commensals during persistent colonization (Figure 4).  
 
Immunomodulation 
In order to persist in the gut, non-pathogenic bacteria that intimately associate with host tissue 
must be tolerated by the immune system. The mucosa is inundated with large amounts of 
secreted immunoglobulin A (sIgA) to monitor the microbiota. Many bacteria in the gut are 
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coated in sIgA, and this subpopulation broadly resembles the mucosal population101. Certain 
adherent species such as Helicobacter spp. and SFB are especially highly coated in sIgA102. 
Binding of sIgA to bacteria may contribute to mucosal biofilm formation, which serves as a 
barrier to pathogen adherence103. Gnotobiotic studies with Rag1 knockout mice (which 
effectively have no adaptive immune system) showed that experimental coating of B. 
thetaiotaomicron with sIgA reduces microbial fitness but also leads to reduced inflammatory 
signaling and changes to bacterial gene expression5,104. Through these mechanisms, sIgA 
mediates homeostasis between the host and the microbiota, as well as potential pathogens at 
mucosal surfaces. Furthermore, natural antibodies have evolved to recognize bacterial 
capsular polysaccharides; while largely studied in the context of infectious agents, such 
antibodies may also represent an evolutionarily conserved strategy used by the host to sense 
indigenous bacterial species. However, examples on how the immune system can 
dependably distinguish between harmful and beneficial microorganisms remain limited. 
 
An alternate view is that the immune system is not “hard-wired” to discriminate between 
various classes of microorganisms, but rather that specific species have adapted to promote 
their own immunologic tolerance. A few examples of active, species-specific 
immunomodulation by beneficial microorganisms suggest that some bacteria display signals 
that ensure their own tolerance by the immune system (Figure 5). B. fragilis is one of the 
best-understood gut bacteria in terms of immunomodulation. A component of its capsule, 
polysaccharide A (PSA), signals through an antigen-presenting cell intermediary to stimulate 
production of IL-10 by an anti-inflammatory subset of immune cells, regulatory T cells105, 
contributing to the ability of B. fragilis to enter the mucus layer of the colon45 (Figure 5). 
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Surface fucosylation of the bacterial capsule also contributes to B. fragilis fitness in the gut, 
perhaps by mimicking the host cell surface to elicit a tolerogenic immune response106. 
Through these specific molecular signals, B. fragilis induces an anti-inflammatory immune 
profile that facilitates its own colonization. Similarly, exopolysaccharides of Bifidobacterium 
breve promote immune tolerance by decreasing the production of pro-inflammatory 
cytokines and preventing a B-cell response107 (Figure 5). Through a less well-defined 
mechanism, B. breve also induces IL-10 production by regulatory T cells108. Notably, both 
B. fragilis and species of Bifidobacterium are known to closely associate with the host, which 
may necessitate immunomodulation to prevent an inflammatory reaction against these 
bacteria. Similarly, adherent SFB stimulate the development of a subset of T helper cells, 
Th17 cells, which are required for normal SFB colonization and also confer resistance to the 
pathogen Citrobacter rodentium84 (Figure 5; Box 1). Clostridia are able to induce regulatory 
T cells, but a population of many species is much more effective than single isolates or 
combinations of a few, suggesting this is a combined effect of production of different 
metabolites, such as short chain fatty acids, by different species (see below)109 (Figure 5). 
Similarly, a defined community of eight mouse gut bacterial species (including several 
members of families Clostridiaceae and Lactobacillaceae) referred to as the altered 
Schaedler’s flora110, was also shown to modulate immune responses mediated by regulatory 
T cells. Therefore, it is likely that many other beneficial microorganisms have co-evolved 
with the immune system to facilitate stable long-term colonization. 
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Figure 5: Immunomodulation by commensal gut bacteria. Commensal gut bacteria induce 
immunomodulation via interaction with epithelial cells, antigen presenting cells (such as 
dendritic cells (DCs)), and via production of signaling metabolites. The exopolysaccharides 
of adherent Bifidobacterium breve reduce the production of inflammatory cytokines to 
dampen B cell responses. The capsular polysaccharide PSA of Bacteroides fragilis and short-
chain fatty acids (SCFAs) produced by many species of Clostridia (and other genera) 
stimulate the production of the anti-inflammatory interleukin-10 (IL-10) by regulatory T 
cells. Segmented filamentous bacteria (SFB) intercalate between microvilli of epithelial cells 
and stimulate the development of Th17 cells, which are important for mucosal immunity to 
extracellular pathogens. 
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Several non-specific signals in the gut also promote tolerance towards beneficial 
microorganisms. Short chain fatty acids such as butyrate, propionate, and acetate are the end-
products of anaerobic fermentation of sugars, which is the dominant metabolism in the colon. 
The development of regulatory T cells is stimulated by these molecules111,112, which could 
be a more general way for the immune system to recognize beneficial bacteria or to assess 
the total fermentative productivity of the community. Mucus is another non-specific anti-
inflammatory signal. When MUC2 is taken up by dendritic cells in mice, it inhibits the 
expression of pro-inflammatory signals113, raising the possibility that indigenous mucin-
degraders may induce host tolerance by being co-presented with mucus. Pathogens also have 
an arsenal of anti-inflammatory mechanisms to suppress the immune system to promote 
infection114. Particularly perplexing is the fact that features traditionally regarded as virulence 
factors in pathogens, such as capsular polysaccharides and pili, are also colonization factors 
in beneficial bacteria. Our notion of the defining characteristics of pathogens is likely 
clouded by a historical under-appreciation of similar colonization strategies used by 
beneficial species (Figure 4). It is not surprising that similar mechanisms of host association 
(mucus penetration, adherence, immune modulation) are used by pathogenic and commensal 
bacteria alike; however, a key distinguishing feature is that commensals have either not 
evolved traits resembling traditional virulence factors, or have evolved additional features or 
modifications to offset the host-response to such factors. This perspective suggests that 
commensal bacteria may have reached an immunologic and metabolic ‘truce’ with their host, 
enabling persistent establishment of defined microbial habitats and elaborate microbial 
biogeographies. 
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MICRO-BIOGEOGRAPHY IN HEALTH AND DISEASE 
Microhabitats in the gut are likely to contribute to the development and stability of microbial 
communities because spatially stratified niches facilitate greater diversity. In mouse pups, 
the fecal microbiota is initially dominated by Proteobacteria, a signature of the small 
intestine, but switches following weaning to Clostridia and Bacteroides, which are 
characteristic of the adult colon2. The sequential development of the microbiota thus may 
occur from proximal to distal compartments, which makes sense as dispersal in the gut is 
largely unidirectional along the fecal stream. Because of this restriction on dispersal, 
depletion of beneficial species, especially in the colon, could be catastrophic without a 
mechanism to replenish the community. Therefore, protected regions that are less susceptible 
to variable conditions in the gut may serve as reservoirs of bacterial cells that can seed growth 
in the lumen, possibly after an environmental insult (Figure 6). In the case of B. fragilis, 
mutants that are unable to colonize the crypts of the colon are less resilient to intestinal 
perturbations such as antibiotic treatment and enteric infection46. This is also a proposed 
function of the human appendix, which has a mucus and bacteria-filled lumen contiguous 
with the cecum115. The appendix is protected from the fecal stream, yet harbors a diverse 
microbial community and a contingent of specialized immune cells. The appendix is also 
phylogenetically widespread and evolved independently at least twice, providing strong 
evidence that this is not a vestigial structure as once believed27. In the rabbit appendix, 
indigenous bacteria coordinate the education of B and T-lymphocytes, suggesting that these 
tissue-associated niches are venues for immunomodulation116. Microhabitats such as crypts, 
mucus, and the appendix may be crucial to facilitate immune homeostasis, protect microbial 
inhabitants from competitors, and re-populate the gut following catastrophic perturbations 
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that alter bacterial community structure or deplete certain species from the lumen. 
 
 
Figure 6: Gut microhabitats as reservoirs of bacterial diversity. Specific niches such as 
crypts, the inner mucus, and the appendix may be crucial to facilitate immune homeostasis, 
protect microbial inhabitants from competitors, and re-populate the gut following 
perturbations that alter bacterial community structure or deplete certain species from the 
lumen. A) A subset of species is able to penetrate the inner mucus layer and enter crypt 
spaces. B) Environmental challenges such as diet perturbations, abnormalities in 
gastrointestinal motility, and antibiotic consumption massively alter the lumen community. 
However, the more stable mucosal environment and crypts protect important bacterial 
species. C) The crypts and mucosa serve as reservoirs to repopulate the lumen. 
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Micro-biogeography alterations during disease 
The adverse effects of altered composition of the healthy microbiota, known as dysbiosis, on 
host health have long been appreciated. Increasing clinical evidence links dysbiosis with 
various immune, metabolic, and neurological disorders in both intestinal and extra-intestinal 
sites. For example, inflammatory bowel disease (IBD) is associated with changes in the gut 
microbiota, characterized by decreased abundance of Clostridia117-119 and overall reduction 
in bacterial diversity118-120. Childhood asthma is correlated with low intestinal microbial 
diversity during the first month of life121. The obesity-associated microbiota is characterized 
by reduced microbial diversity and, in some studies, an increased Firmicutes:Bacteroidetes 
ratio122. In recent years, the role of gut dysbiosis in the pathogenesis of chronic liver diseases 
123,124, colorectal cancer (CRC) 125,126, and even neuropsychiatric dysfunctions127 has been 
explored in animal models and humans. For clinical applications, profiling of the fecal 
microbiota has been widely used as a surrogate for the gastrointestinal bacterial community 
due to non-invasive and straightforward sample collection; however, fecal populations may 
be less informative than mucosal biopsies in defining disease-associated dysbiosis128, a 
notion that requires additional experimental support. Below, we detail two examples that 
illustrate the importance of micro-biogeography alterations of the gut microbiota during 
disease: IBD and hepatic encephalopathy. 
 
IBD is characterized by inflammation of the gastrointestinal tract resulting in pain, vomiting, 
diarrhea, and other complications including severe weight loss and behavioral changes. 
Generally, IBD is categorized into two syndromes, Crohn’s disease, which may involve 
inflammation throughout the gastrointestinal tract (mouth to anus), and ulcerative colitis, 
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where pathology is restricted to the large intestine. For over a decade, studies have attempted 
to define a pattern of dysbiosis associated with IBD and yielded inconsistent and sometimes 
contradicting results129. Studies that focused on fecal microbiota reported wide inter-
individual differences in composition with overall microbial diversity reduced118 in Crohn’s 
disease patients compared to healthy controls. However, a study in which human gut 
microbiota were assessed for the ability to drive colitis pathology in mice found that bacteria 
contributing to the disease are highly coated in sIgA102, suggesting that the mucosal or tissue-
associated population is most relevant. Human studies based on biopsy samples elucidated 
several consistent features in line with this hypothesis: patients had increased concentration 
of bacteria on the mucosal surface130; decreased microbial diversity; 119,120; decreased 
abundance of Clostridium species 117; and increased number of Enterobacteriaceae 
(especially adherent, invasive E. coli) in ileal mucosa131. Most recently, both the lumen- and 
mucosa-associated microbiota were profiled in a large cohort of new-onset, treatment naïve 
pediatric patients with Crohn’s disease and non-IBD controls. Analysis of the mucosal 
microbiota revealed a significant drop in species richness, an increase in Enterobacteriaceae, 
a decrease in Clostridiales, and significant changes in several other previously unidentified 
taxa. Importantly, these dysbiotic signatures were lost when stool samples were examined128. 
Intriguingly, a laser-capture microdissection study of colon crypt mucus in patients with 
ulcerative colitis found that they had lower levels of crypt-associated bacteria132. Overall, 
these studies highlight that distinguishing between fecal and mucosal microbial communities 
is particularly important for finding a reproducible microbial signature of IBD. Moving from 
correlations to a potential causal etiology of the microbiota for IBD and other disorders will 
require further study of mucosal communities, focusing on the interactions between the host 
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and microbiota. 
 
Biogeographical changes in the gut microbiota may also influence liver function. Hepatic 
encephalopathy is a neuropsychiatric complication of cirrhosis and direct sequelae of gut 
dysbiosis. As a result of impaired liver function and the presence of porto-systemic shunts 
(bypass of the liver by the circulatory system), toxic metabolites produced by the gut 
microbiota evade liver catabolism and cross the blood-brain barrier, leading to cerebral 
toxicity123. Interestingly, a comparison of the fecal microbiota of cirrhotic patients with and 
without hepatic encephalopathy showed minimal differences, whereas analyzing the 
microbiota composition of the colonic mucosa revealed significant changes, including lower 
Roseburia and higher Enterococcus, Veillonella, Megasphaera, Burkholderia, and 
Bifidobacterium in cirrhotic patients with hepatic encephalopathy133. The bacterial genera 
over-represented in the mucosa of patients with hepatic encephalopathy (Megaspheara, 
Veillonella, Burkholderia, and Bifidobacterium) were also correlated with poor cognition, 
higher inflammation, and higher clinical severity score. In summary, mucosal dysbiosis in 
the gut, but not in the composition of the fecal community, significantly correlates with the 
severity of chronic liver disease phenotypes, including hepatic encephalopathy. 
 
CONCLUSION 
We have highlighted evidence that the microbiota is biogeographically stratified within the 
gut on different spatial scales and axes. Progress towards a functional understanding of the 
microbiota necessitates increased attention to microhabitats within the gut ecosystem, and to 
spatial relationships between microorganisms and between microorganisms and the host. 
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Fecal community profiling enabled by next-generation sequencing provides a valuable 
picture of the diversity, specificity, stability, and developmental dynamics of the gut 
microbiota, but focusing on measurements of abundance in feces neglects the importance of 
mucus and tissue-associated organisms and cannot account for spatial distributions. 
Similarly, studies in gnotobiotic animals allow a reductionist approach to studying host-
microorganism interactions akin to methods traditionally employed by microbiologists 
studying pathogens, but this simplified methodology is likely to miss important contributions 
from interspecies interactions. The functional study of gut microbial ecology using “meta-
omics” techniques enables one to account for the behaviors of the community as a whole, 
but attributing functions to particular microbial members remains a challenge in community-
level ecology. Therefore, testing unifying hypotheses using both reductionist and ecological 
approaches will be essential to our understanding of the microbiota and its biological 
functions. 
 
More than half a century ago, in “Microorganisms Indigenous to Man,” the microbiologist 
Theodor Rosebury lamented on the lack of a general theory for influences that control 
composition of the microbiota, the roles of individual members, and functions that affect the 
host134. With the true complexity of the problem revealed recently by sequencing advances, 
research is only now in a position to fulfill Rosebury’s call for a general theory. Rolf Freter’s 
nutrient niche hypothesis135, which states that limiting nutrients control the population level 
of species that are particularly adept at utilizing them, provides a metabolic foundation to 
explain some of the nascent observations in the field. But when Freter proposed his ideas, 
we were unaware of the role of immunomodulation by non-pathogens, which requires access 
 37 
to the tissue. Based on evidence outlined in this review, we propose that the host presents 
limiting nutrients as well as attachment sites in privileged locations. Furthermore, the 
immune system has an active role in allowing only beneficial species to access these 
locations during homeostasis. Selection for particular species close to the epithelium creates 
protected, stable reservoirs for microorganisms to persist in the face of rapidly changing 
conditions in the gut lumen. Through localized, immune-facilitated, and adherence-
dependent nutrient selection, the host maintains stability of a diverse community of microbial 
symbionts. 
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Abstract 
The immune system responds vigorously to microbial infection, while permitting life-long 
colonization by the microbiome. Mechanisms that facilitate the establishment and stability 
of the gut microbiota remain poorly described. We discovered that a sensor/regulatory 
system in the prominent human commensal Bacteroides fragilis modulates its surface 
architecture to invite binding of immunoglobulin A (IgA). Specific immune recognition 
facilitated bacterial adherence to cultured intestinal epithelial cells and intimate association 
with the gut mucosal surface in vivo. The IgA response was required for B. fragilis, and 
other commensal species, to occupy a defined mucosal niche that mediated stable 
colonization of the gut through exclusion of exogenous competitors. Therefore, in addition 
to its role in pathogen clearance, we propose that IgA responses can be co-opted by the 
microbiome to engender robust host-microbial symbiosis. 
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Main Text 
At birth, ecological and evolutionary processes commence to assemble a complex 
microbial consortium in the animal gut. Community composition of the adult human gut 
microbiome is remarkably stable during health, despite day-to-day variability in diet and 
diverse environmental exposures. Instability, or dysbiosis, may be involved in the etiology 
of a variety of immune, metabolic, and neurologic diseases (1, 2). Longitudinal sequencing 
studies indicate a majority of bacterial strains persist within an individual for years (3), and 
for most species there is a single, persistently dominant strain (4) (termed “single-strain 
stability"). Mucus and components of the innate and adaptive immune systems are thought 
to influence microbiome stability, independently of diet. For example, immunoglobulin A 
(IgA), the main antibody isotype secreted in the gut, shapes the composition of the 
intestinal microbiome via currently unknown mechanisms (5-8). IgA deficiency in mice 
increases inter-individual variability in the microbiome (9) and decreases diversity (10, 
11). The direct effects of IgA on bacteria have largely been studied in the context of enteric 
infection by pathogens (12). However, early studies of IgA in the healthy gut found that 
the majority of live bacterial cells in feces are bound by IgA (13), reflecting a steady-state 
IgA response to persistent indigenous microbes (14). Studies show that IgA promotes 
adherence of commensal bacteria to tissue-cultured intestinal epithelial cells (15, 16), 
though the in vivo implications of this observation are unclear. Furthermore, lack of IgA, 
the most common human immunodeficiency, does not affect lifespan and only modestly 
increases susceptibility to respiratory and gastrointestinal infections (17), raising the 
question of why the immune system evolved to invest the considerable energy to produce 
several grams of IgA daily (18). 
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Bacteroides fragilis is an important member of the human gut microbiome, with beneficial 
properties that ameliorate inflammatory and behavioral symptoms in preclinical animal 
models (19-22). This commensal exhibits remarkable single-strain stability (23, 24) and 
enriched colonization of the gut mucosal surface (25). To explore physical features of B. 
fragilis interaction with the host epithelium, we used transmission electron microscopy 
(TEM) to visualize colonic tissues of mono-colonized mice. B. fragilis commonly formed 
discrete aggregates of tightly-packed cells on the apical epithelial surface (Fig. 1A) and 
penetrated the glycocalyx layer of transmembrane mucins, nearly contacting the microvilli 
(Fig. 1B and fig. S1A and B). Intact B. fragilis cells were also found nestled in the ducts 
of the crypts of Lieberkühn (Fig. 1C and S1C). We previously identified a genetic locus in 
B. fragilis, named the commensal colonization factors (ccfABCDE), which is necessary for 
colonization of colonic crypts (26). To assess how these genes affect bacterial localization 
to the mucosal surface, we mono-colonized mice with a ccfCDE (∆ccf) mutant. By TEM, 
B. fragilis ∆ccf was only found as sparse, individual cells within the epithelial mucosa, 
excluded from contact with the glycocalyx (Fig. 1D and E), and never observed in 
aggregates as for wild-type bacteria (Fig. 1F). B. fragilis burden in the colon lumen was 
identical between strains (fig. S2A), suggesting that the CCF system is required specifically 
for bacterial aggregation within mucus. 
 
High-resolution tomograms of bacterial cells in vivo revealed the presence of a thick, fuzzy 
capsule layer covering wild-type B. fragilis (Fig. 1G), which was significantly reduced in 
B. fragilis ∆ccf (Fig. 1H and 1I). We sought to investigate the bacterial physiology 
underlying this ultrastructural change, and potential corresponding effects on colonization. 
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The ccf locus is highly induced during gut colonization (26) and bacterial growth in mucin 
O-glycans (27), indicating the CCF system may sense a specific host-derived glycan. The 
ccf genes are homologous to polysaccharide utilization systems in which a sigma factor 
(ccfA) is activated by extracellular glycan sensing (28), thus we hypothesized that ccfA may 
activate genes involved in mucosal colonization. We overexpressed ccfA in B. fragilis and 
assessed global gene expression by RNAseq during in vitro growth (without 
overexpression ccf is poorly expressed in culture (26)). Of the non-ccf genes regulated by 
ccfA, 24 out of 25 genes mapped to the biosynthesis loci for capsular polysaccharides A 
and C (PSA and PSC) (Fig. 2A, 2B and Table S1). Correspondingly, ccf mutation 
decreased expression of PSC and increased expression of PSA in vivo (Fig. 2C). While 
phase variation of capsular polysaccharides is known to influence general in vivo fitness of 
B. fragilis (29, 30), these studies identify a pathway for transcriptional regulation of 
specific polysaccharides in the context of mucosal colonization. 
 
We modeled single-strain stability using a horizontal transmission assay, wherein co-
housing animals respectively harboring isogenic strains of wild-type B. fragilis resulted in 
minimal strain transmission from one animal to another (Fig. 2D, S2A). This intra-species 
colonization resistance is provided through bacterial occupation of a species-specific 
nutrient or spatial niche (26). However, as previously reported (26), if mice are colonized 
initially with B. fragilis ∆ccf, animals were permissive to co-colonization by wild-type B. 
fragilis after co-housing (Fig. 2E, S2B), indicating a CCF-dependent defect in niche 
saturation. Mice harboring a mutant in the biosynthesis genes for PSC (∆PSC) showed 
highly variable co-colonization by wild-type bacteria (Fig. 2F, S2C). Interestingly, we 
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observed an unexpected increase in expression of the PSB biosynthesis genes in this mutant 
(Fig. 2H), which may compensate for the loss of PSC. We generated a strain defective in 
synthesizing both PSB and PSC (∆PSB/C), and mice mono-associated with the double 
mutant were consistently unable to maintain colonization resistance (Fig. 2G, S2D-F), 
though the strain retained ccf expression (fig. S2G). Despite lack of competition in a mono-
colonized setting and equal levels of colonization in the colon lumen (fig. S2H), the B. 
fragilis ∆ccf and ∆PSB/C strains were defective in colonization of the ascending colon 
mucus (Fig. 2I), reflecting impaired saturation of the mucosal niche. Accordingly, when 
we imaged the ∆PSB/C strain in vivo employing TEM, though the capsule was not as thin 
as in B. fragilis ∆ccf (fig. S2I and J), the hallmark epithelial aggregation phenotype was 
abrogated compared to wild-type bacteria (fig. S2K and L). Therefore, we conclude that 
the CCF system regulates capsule expression to mediate B. fragilis mucosal colonization 
and single strain stability. 
 
To investigate host responses contributing to mucosal colonization, we defined the 
transcriptome of the ascending colon during colonization with wild-type B. fragilis or B. 
fragilis ∆ccf. Remarkably, 7 of the 14 differentially expressed genes encode 
immunoglobulin variable chains (Fig. 3A and table S2). We did not observe any elevation 
of immune responses in ∆ccf–colonized mice (fig. S3A), indicating that changes in 
mucosal association are not caused by inflammation. Accordingly, we tested whether 
capsular polysaccharide regulation by ccf affects IgA recognition of bacteria (31-33). In 
fecal samples from mono-colonized animals, wild-type B. fragilis was highly coated with 
IgA, which was significantly diminished in ∆ccf and ∆PSB/C strains (Fig. 3B, 3C, and 
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S4A). We observed no difference between these strains in the induction of total fecal IgA 
(Fig. 3D), reflecting equivalent stimulation of nonspecific IgA production (10, 34, 35). To 
test bacteria-specific responses, IgA extracted from feces of mice mono-colonized with B. 
fragilis was evaluated for binding to bacteria recovered from mono-colonized Rag1-/- mice 
(in vivo-adapted, yet IgA-free bacteria). Western blots of bacterial lysates showed that 
strong IgA reactivity to capsular polysaccharides was abrogated in the ∆ccf and ∆PSB/C 
strains (Fig. 3E and F). Although IgA can be polyreactive (10, 34, 35), binding to lysates 
of Bacteroides was species-specific (fig. S4B) and required induction of IgA following 
bacterial colonization (fig. S4C and D). Accordingly, in a whole bacteria binding assay, 
IgA induced by wild-type bacteria maximally coated wild-type B. fragilis compared with 
the ∆ccf and ∆PSB/C strains (Fig. 3G). IgA induced by B. fragilis ∆ccf exhibited reduced 
binding to wild-type bacteria (Fig. 3G). The addition of IgA to in vivo-adapted, IgA-free 
bacteria increased adherence of B. fragilis to intestinal epithelial cells in tissue culture (Fig. 
3H), yet had no effect on bacterial viability (fig. S4E). Cell lines known to produce more 
mucus (36) exhibited a greater capacity for IgA-enhanced B. fragilis adherence (fig. S4F), 
consistent with prior work showing that IgA binds mucus (36-38). Importantly, IgA-
enhanced adherence was decreased if targeted bacteria lack ccf or PSB/C, or if the IgA 
tested was induced by a ccf mutant or Bacteroides thetaiotaomicron (Fig. 3H and S4G). 
While pathogenic bacteria elaborate capsular polysaccharides for immune evasion, these 
results suggest B. fragilis deploys specific capsules for immune attraction, potentially 
enabling stable mucosal colonization.  
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We determined whether IgA coating promotes B. fragilis colonization in mice. Using the 
horizontal transmission paradigm, Rag1-/- mice colonized with wild-type B. fragilis were 
readily co-colonized by an isogenic strain from a co-housed animal (fig. S5A and B), 
showing loss of colonization resistance in the absence of adaptive immunity. We next 
treated wild-type mice with an anti-CD20 antibody (fig. S5C) (39) to deplete B cells (fig. 
S5D-F), thus reducing total fecal IgA levels (fig. S5G) and eliminating IgA coating of wild-
type B. fragilis during mono-colonization (Fig. 4A). IgA recovered from isotype control 
treated mice, also mono-colonized with B. fragilis, promoted adherence of wild-type 
bacteria to epithelial cells in vitro, while IgA from anti-CD20 treated mice had no effect 
despite being exposed to B. fragilis antigens (Fig. 4B). In the horizontal transmission assay, 
B cell depleted mice mono-colonized with B. fragilis were readily invaded by wild-type 
bacteria, while isotype control-injected animals retained colonization resistance (Fig. 4C 
and S5H). Therefore, active B cell responses to B. fragilis colonization enhance single-
strain stability. 
 
As B cell depletion eliminates all antibody isotypes, germ-free IgA-/- mice (40) were 
generated and mono-colonized with B. fragilis. We did not observe compensatory coating 
by IgM (fig. S6A). In a horizontal transmission assay with wild-type (BALB/c) and IgA-/- 
mice, lack of IgA allowed co-colonization by challenge strains (Fig. 4D, S6B-D), 
indicating that IgA specifically contributes to single-strain stability. This feature was 
reproduced in mice with a full microbial community “spiked” with genetically marked B. 
fragilis strains (fig. S6E and F), revealing that single-strain stability of an individual 
bacterial species occurs in the context of a complex community. Mono-colonized IgA-/- 
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mice harbored reduced levels of live bacteria in the colon mucus compared to wild-type 
mice (Fig. 4E), though they had greater numbers of bacteria in the colon lumen (fig. S6G). 
TEM images of ascending colon tissues reveal that in IgA-/- animals, wild-type B. fragilis 
failed to aggregate on the epithelial surface (Fig. 4F and 4G), similar to the ccf and PSB/C 
mutants in wild-type animals. B. fragilis cells also formed aggregates in feces in the 
presence of IgA (fig. S7), indicating that enhanced mucosal colonization may be due to 
increased aggregation or growth (41) within mucus. These findings converge to support a 
model whereby ccf regulates expression of specific capsular polysaccharides to attract IgA 
binding, allowing for robust mucosal colonization and single-strain stability. 
 
Beyond B. fragilis, we tested whether IgA shapes a complex microbiome following 
controlled introduction of mouse microbiota to germ-free BALB/c or IgA-/- mice. One 
month following colonization, despite similar microbiome profiles in feces of both mouse 
genotypes (fig. S8A), we observed differences for specific taxa (Table S3). We also 
identified a defect in community stratification between the colonic mucus and lumen of 
IgA-/- mice (Fig. 4H and S8B), revealing that IgA is required to individualize microbiome 
profiles between these two anatomic locations. Remarkably, a highly mucus-enriched exact 
sequence variant (ESV), mapping uniquely to B. fragilis, was significantly decreased in the 
mucus of IgA-/- mice compared to BALB/c mice (Fig. 4I and S9A), naturally supporting 
our observations from mono-colonized mice. To extend this analysis to other microbial 
species, we identified Rikanellaceae, Blautia sp., and segmented filamentous bacteria 
(SFB) as being highly IgA-coated (fig. S9B) (35), and assessed the abundance of these taxa 
in the colonic or ileal mucus. Blautia sp. and segmented filamentous bacteria (SFB) 
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displayed increased mucosal association in the absence of IgA (Fig. 4I) (42), demonstrating 
that IgA can protect the intestinal barrier. However, similar to B. fragilis, Rikanellaceae 
were highly abundant in colon mucus and significantly depleted in IgA-/- mice (Fig. 4I). 
We conclude that IgA-enhanced mucosal colonization occurs within complex communities 
for multiple strains of B. fragilis and other species of the gut microbiome. 
 
Classically viewed, the immune system evolved to prevent microbial colonization. 
However, not only do animals tolerate a complex microbiome, in the case of B. fragilis 
provoking an immune response paradoxically enables intimate association with its 
mammalian host. Related commensal bacteria may also benefit from actively engaging IgA 
during symbiosis, as Rag2-/- mice devoid of adaptive immunity harbor fewer Bacteroides 
(43), and both B cell deficient and IgA-/- animals display decreased colonization by the 
Bacteroidaceae family (44). IgA has been previously shown to increase adherence of 
Escherichia coli (15), Bifidobacterium lactis, and Lactobacillus ramnosus (16) to tissue-
cultured epithelial cells, suggesting that these microorganisms may also benefit from IgA 
to establish a mucosal bacterial community. Mucosal microbiome instability or loss of 
immunomodulatory species may underlie the link between IgA deficiency and autoimmune 
diseases in humans (45). Interestingly, while IgA-coated bacteria from individuals with 
IBD (46) or nutritional deficiencies (47) exacerbate respective pathologies in mice, IgA-
coated bacteria from healthy humans protect mice from disease (47). We propose that 
during health, IgA fosters mucosal colonization of microbiota with beneficial properties (9), 
while disease states may induce (or be caused by) IgA responses to pathogens or pathobionts 
that disrupt healthy microbiome equilibria. Indeed, computational models indicate that IgA 
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can both maintain indigenous mucosal populations and clear invasive pathogens (48). In 
addition to serving as a defense system, we discover that adaptive immunity evolved to 
engender intimate association with members of the gut microbiome. 
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Fig. 1. Bacteroides fragilis resides as aggregates on the colon epithelium in a CCF-
dependent manner. (A) Representative transmission electron microscopy (TEM) 
projection and (B) high-resolution tomogram of epithelial-associated wild-type B. fragilis 
in mono-colonized mice. Ascending colons of mice harbored aggregates of B. fragilis 
(green arrow) under non-pathogenic conditions that made tight associations with the 
glycocalyx (yellow line) overlying intestinal epithelial cells (IECs, yellow arrow). (C) 
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Tomogram of wild-type B. fragilis penetrating deep into the duct of a crypt of Lieberkühn. 
(D) Representative TEM projection image and (E) tomogram of epithelial-associated B. 
fragilis ∆ccf. The absence of the CCF system abrogated formation of bacterial aggregates 
and prevented intimate association with the glycocalyx. (n = 3 mice per group, about 1 mm 
epithelium scanned per mouse). (F) Quantification of bacterial cells per projection montage 
(A and D) of epithelial-associated bacteria (unpaired t test, n = 7, 8 images from 4 mice per 
group). (G and H) Tomogram of the bacterial surface of wild-type B. fragilis (G) in 
comparison to B. fragilis ∆ccf (H) revealed a thick fuzzy capsule for wild-type bacteria 
residing in the colons of mice. (I) Measurement of capsule thickness (unpaired t test, n = 
10 cells from 3 mice per group) (*** p < 0.001). 
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Fig. 2. Specific capsular polysaccharides, regulated by ccf, are necessary for single-
strain stability. (A) RNAseq gene expression analysis of B. fragilis overexpressing ccfA 
during laboratory culture growth, relative to empty vector control (n = 3). Green symbols 
represent PSA genes; red symbols represent PSC genes; blue symbols represent ccf genes. 
(B) Heat map of expression levels for all capsular polysaccharide loci in B. fragilis 
following ccfA overexpression during growth in culture. (C) Relative expression using 
qRT-PCR (∆∆Ct normalized to gyrase) of RNA from colon lumen contents of mice mono-
colonized with B. fragilis or B. fragilis ∆ccf (Sidak 2-way ANOVA, n = 4). (D-G) 
Abundance of foreign strains exchanged between pairs of co-housed mice each mono-
colonized with the indicated strains, in colony forming units (CFU) per gram of feces 
(Sidak repeated measure 2-way ANOVA on log-transformed data, geometric mean and 
95% CI, n = 9-12 pairs per plot). (H) Relative expression levels of capsular polysaccharides 
analyzed by qRT-PCR (∆∆Ct normalized to gyrase) of RNA from colon lumen contents of 
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mice mono-colonized with B. fragilis or B. fragilis ∆PSC (Sidak 2-way ANOVA, n = 3, 
4). (I) Plating of CFU from ascending colon mucus of mice mono-colonized with B. fragilis 
strains (Tukey ANOVA, n = 8) (* p < 0.05, ** p < 0.01, *** p < 0.001). 
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Fig. 3. B. fragilis induces a specific IgA response, dependent on ccf regulation of 
surface capsular polysaccharides, which enhances epithelial adherence. (A) RNAseq 
gene expression analysis of RNA recovered from whole ascending colon tissue of mice 
mono-colonized with B. fragilis or B. fragilis ∆ccf (n = 3). (B) Flow cytometry plots and 
(C) quantification of IgA coating of B. fragilis from feces of mice mono-colonized with 
various strains (Tukey ANOVA, n = 11-12). (D) ELISA for total fecal IgA in mono-
colonized mice (Sidak repeated measure 2-way ANOVA, not significant, n = 4). (E) 
Bacterial lysates from feces of mono-colonized Rag1-/- mice probed in Western blots with 
fecal IgA from B. fragilis mono-colonized mice and (F) quantification of the proportional 
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signal from IgA binding to capsular polysaccharides (CPS) (over 245 kDa) (Tukey 
ANOVA, n = 3 mice). (G) Binding of fecal IgA extracted from mono-colonized mice to 
various strains of B. fragilis. Source of IgA is mice colonized with either WT B. fragilis or 
B. fragilis ∆ccf. Because ccf is expressed in vivo, IgA-free bacteria from feces of mono-
colonized Rag1-/- mice were used as the target for IgA binding (Tukey 2-way ANOVA, 
*significantly different from WT bacteria with WT IgA, n = 3). (H) In vitro epithelial cell 
adherence assay using IgA extracted from Swiss Webster mice (or Rag1-/-, second column) 
mono-colonized with B. fragilis or B. thetaiotaomicron (theta; last column). IgA-free but 
in vivo-adapted bacteria were isolated from mono-colonized Rag1-/- mice (Tukey ANOVA, 
n = 4 mice as the source of bacteria) (* p < 0.05, ** p < 0.01, *** p < 0.001). 
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Fig. 4. IgA production in vivo is necessary for single-strain stability, mucosal 
colonization, and epithelial aggregation. (A) IgA coating of wild-type B. fragilis in feces 
following injection of anti-CD20 or isotype control antibody (unpaired t test, n = 8). (B) 
Epithelial cell adherence assay of wild-type B. fragilis incubated with IgA extracted from 
indicated mono-colonized mice (Tukey ANOVA, n = 4 mice as the source of bacteria). (C) 
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Abundance of foreign strains exchanged between pairs of wild-type B. fragilis mono-
colonized mice treated with anti-CD20 or an isotype control (Sidak repeated measure 2-way 
ANOVA on log-transformed data, n = 10). (D) Foreign strains exchanged between pairs of 
BALB/c and BALB/c IgA-/- mice mono-colonized with wild-type B. fragilis (Sidak repeated 
measure 2-way ANOVA on log-transformed data, n = 9). (E) CFU plating of ascending colon 
mucus of wild-type and IgA-/- mice mono-colonized with wild-type B. fragilis (unpaired t 
test, n = 9). (F) Representative TEM projections of ascending colon (yellow arrow: epithelial 
cell) from mice mono-colonized with wild-type B. fragilis (green arrow) (n = 3 mice per 
group, about 1 mm epithelium scanned per mouse) and (G) quantification of bacterial cells 
per projection montage (unpaired t test, n = 7, 6 images from 3 mice per group) (H) Principle 
coordinate analyses of weighed UniFrac distances of 16S community profiles of ex-germ-
free BALB/c and BALB/c IgA-/- mice transplanted with a complex mouse microbiota 
(Adonis test within colon for lumen/mucus difference). (I) Relative abundance of B. fragilis 
and highly IgA-coated ESVs in ex-germ-free mice (* p < 0.05, ** p < 0.01, *** p < 0.001).  
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Fig. S1. Additional EM images from mice mono-colonized with wild-type B. fragilis. 
(A and B) Example aggregates of B. fragilis on the epithelial surface in projection images 
(left) with high resolution tomograms of the marked region (right). Arrows indicate 
examples of bacteria penetrating the glycocalyx. (C) Projection and inset tomogram of an 
additional example of B. fragilis in a crypt of Lieberkühn. 
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Fig. S2. Additional in vivo phenotypes for various B. fragilis strains. (A) Abundance of 
the initial strains corresponding to Fig. 2D, (B) Fig. 2E, (C) Fig. 2F, and (D) 2G (n = 9-
12). (E) Abundance of foreign strains in mice originally mono-colonized with indicated 
strain (n = 6) and challenged by gavage. (F) Abundance of the original strains 
corresponding to E (geometric mean and 95% confidence interval plotted for all line graphs 
with Sidak repeated measure 2-way ANOVA on log-transformed data). (G) qRT-PCR 
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analysis for ccf expression of RNA extracted from colon lumen contents of mono-
colonized mice, indicating that PSB/C mutation does not affect ccf expression (Tukey 
ANOVA, n = 3). (H) Quantification of bacteria in the colon lumen of mono-colonized 
mice, corresponding to Fig. 2I (Tukey ANOVA, n = 8). (I) High resolution tomogram 
(image width = 600 nm) of B. fragilis ∆PSB/C in the colon mucosa of a mono-colonized 
mouse and (J) quantification of the capsule thickness including data from Fig. 1I for wild-
type and ∆ccf (Tukey ANOVA, n = 10). (K) Example projection montage of the apical 
surface of the epithelium of mice mono-colonized with B. fragilis ∆PSB/C shows 
aggregates of only small numbers of bacteria. (L) Quantification of number of epithelial 
associated bacteria including data from Fig. 1F for wild-type and ∆ccf (Tukey ANOVA, n 
= 7, 8, 8 images from 4 mice per group) (* p < 0.05, ** p < 0.01, *** p < 0.001). 
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Fig. S3. Host inflammatory profiles of B. fragilis and B. fragilis ∆ccf show no 
differences. (A) Expression levels of inflammatory cytokines, lysozyme, and antimicrobial 
peptides from ascending colon RNAseq of mice mono-colonized with B. fragilis or B. 
fragilis ∆ccf reveal an indistinguishable inflammatory response (n = 3). Beta-defensins, 
TNF alpha, IL-1, and IL-6 were not expressed at detectable levels.  
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Fig. S4. Interactions between IgA and B. fragilis. (A) Gating strategy for assessing IgA 
coating of bacteria. Gates were defined using single-stained samples. (B) Lysates of culture-
grown Bacteroides species (108 CFU loaded per well for all blots) probed in western blots 
with fecal IgA from B. fragilis mono-colonized mice, indicating minimal cross-reactivity to 
other species. (C) Lysates of B. fragilis strains from the feces of mono-colonized Rag1-/- mice 
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probed in western blots with fecal IgA from germ-free and (D) B. thetaiotaomicron mono-
colonized mice, with images overexposed to show minimal binding (blots B-D repeated at 
least 3 times). (E) Plating CFU before and after coating with IgA in vitro suggests no impact 
of IgA on the viability of B. fragilis (Tukey ANOVA, n = 8). (F) Tissue-cultured epithelial 
cell adherence assay with various cell lines (in addition to those used in the main text), using 
wild-type B. fragilis from feces of mono-colonized Rag1-/- mice and IgA from mice mono-
colonized with B. fragilis (Sidak 2-way ANOVA, n = 5 mice as the source of bacteria) (G) 
Additional controls for Fig. 3H (first two bars are the same data as in Fig. 3H) indicate no 
baseline difference in epithelial adherence between strains of B. fragilis from feces of mono-
colonized Rag1-/- mice, without the addition of IgA (Tukey ANOVA, n = 4) (* p < 0.05, ** 
p < 0.01, *** p < 0.001). 
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Fig. S5. B. fragilis colonization phenotypes in RAG1-/- and B cell depleted mice. (A) 
Abundance of foreign strains exchanged between pairs of wild-type B. fragilis mono-
colonized mice, either C57BL/6 (B6) and Rag1-/-, in colony forming units (CFU) per gram 
of feces (geometric mean and 95% confidence interval plotted for all line graphs with Sidak 
repeated measure 2-way ANOVA on log-transformed data, n = 9). (B) Abundance of initial 
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strains corresponding to A. (C) Anti-CD20 experimental timeline with germ-free Swiss 
Webster mice. (D) Gating strategy for quantification of B cells to confirm depletion by 
anti-CD20 antibody and (E) example plots. (F) Quantification of B cells as a proportion of 
cell populations in the peritoneum, mesenteric lymph nodes, and lymphocyte fraction of 
the colon lamina propria (LP) following injection of anti-CD20 or isotype control antibody 
(Sidak 2-way ANOVA, n = 4, 5). (G) IgA concentration in feces as assessed by ELISA 3 
weeks after second injection of anti-CD20 or isotype control antibody (unpaired t test, n = 
7). (H) Abundance of initial strains for Fig. 4C (n = 10) (* p < 0.05, ** p < 0.01, *** p < 
0.001). 
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Fig. S6. In vivo phenotypes for B. fragilis in BALB/C and BALB/c IgA-/- mice. (A) 
Percent of B. fragilis coated in IgM in mono-colonized BALB/c and BALB/c IgA-/- mice 
(unpaired t test, n = 4). (B) Abundance of initial strains corresponding to Fig 4D (geometric 
mean and 95% confidence interval plotted for all line graphs with Sidak repeated measure 
2-way ANOVA on log-transformed data, n = 9). (C) Abundance of foreign strains in mice 
mono-colonized with B. fragilis and challenged by gavage with B. fragilis (n = 5). (D) 
Abundance of initial strains corresponding to C. (E) Abundance of foreign strains of B. 
fragilis in SPF mice colonized with B. fragilis and co-housed (n = 10). (F) Abundance of 
initial strains corresponding to E. (G) Quantification of colon lumen colonization 
corresponding to Fig 4E (unpaired t test, n = 9).  (* p < 0.05, ** p < 0.01, *** p < 0.001). 
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Fig. S7. Aggregation of B. fragilis in vivo is affected by IgA and ccf. (A) Transmission 
electron micrographs of colon lumen contents of Swiss Webster mice mono-colonized with 
B. fragilis or B. fragilis ∆ccf (4 representative images for each). (B) Transmission electron 
A
B
B. fragilis B. fragilis ∆ccf
B. fragilis
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micrographs of feces of BALB/c and BALB/c IgA-/- mice mono-colonized with B. fragilis 
(3 representative images for each). 
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Fig. S8. 16S microbiome profiling of ex-germ-free mice. (A) Principle coordinate 
analysis of weighted UniFrac distances of fecal microbiomes between BALB/c and 
BALB/c IgA-/- mice. (B) Relative abundance of bacterial families in colon and ileal lumen 
and mucus in ex-germ-free BALB/c and IgA-/- mice. Most abundant 12 families assigned 
colors; remaining families assigned random shades of gray. 
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Fig. S9. Analyses of exact sequence variants (ESVs) of interest in ex-germ-free mice. 
(A) Heatmap of relative abundance of ESVs assigned to Bacteroides or Parabacteroides in 
the mucus and lumen of the colon and ileum of BALB/c and BALB/c IgA-/- mice. (B) 
Relative abundance of highly IgA-bound taxa (LEfSe LDA effect size > 2) before and after 
sorting (ESVs in Figure 4I are the most abundant representatives of these taxonomic groups; 
“Candidatus Arthromitus” = SFB).  
A
B
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Table S1. 
Differentially expressed (adjusted p-value <0.05) genes in RNAseq of B. fragilis grown in 
culture with and without overexpression of ccfA. Genes are ordered by the fold-change. 
Locus ID Gene Log2(fold-change) (ccfA 
overexpression / vector) 
Adjusted P-value 
BF3583 ccfA 4.08 2.139E-106 
BF1021 wcfG (PSC) 2.93 1.29145E-15 
BF1009 upcY (PSC) 2.91 9.25035E-13 
BF1011 rmlA2 (PSC) 2.89 1.29145E-15 
BF1023 wcfI (PSC) 2.85 6.7139E-14 
BF1017 wcfD (PSC) 2.81 2.02687E-08 
BF1022 wcfH (PSC) 2.66 4.63823E-10 
BF1024 wcfJ (PSC) 2.44 1.07951E-07 
BF1019 wcfE (PSC) 2.44 5.99448E-07 
BF1012 rmlC1 (PSC) 2.42 4.56061E-06 
BF1015 wcfB (PSC) 2.42 1.98807E-07 
BF1025 wcfK (PSC) 2.42 1.65081E-07 
BF1010 upcZ (PSC) 2.21 1.33346E-05 
BF1020 wcfF (PSC) 2.19 0.000822972 
BF1377 wcfS (PSA) -2.07 0.005651271 
BF1376 wcfR (PSA) -2.15 0.001828779 
BF1369 wzx3 (PSA) -2.18 8.44926E-05 
BF1373 wcfO (PSA) -2.30 2.01292E-06 
BF1374 wcfP (PSA) -2.41 5.18014E-07 
BF1372 wzy3 (PSA) -2.44 9.8695E-08 
BF1370 wcfM (PSA) -2.45 7.08576E-08 
BF1371 wcfN (PSA) -2.45 3.10176E-08 
BF0466 Putative protein -2.48 1.65081E-07 
BF1375 wcfQ (PSA) -2.62 3.87573E-10 
BF1368 upaZ (PSA) -2.67 8.15223E-12 
BF1367 upaY (PSA) -2.75 6.50178E-13 
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Table S2. 
Differentially expressed (adjusted p-value < 0.05) genes in mice mono-colonized with B. 
fragilis or B. fragilis ∆ccf. Genes are ordered by the absolute value of the fold-change.   
Gene Log2(fold-change) 
(WT/∆ccf) 
Adjusted P-value 
Igkv4-61 -4.29 0.003125755 
Igkv8-19 4.18 1.51E-06 
Igkv3-12 -3.99 0.049083696 
Ighv1-70 3.74 2.28E-07 
Ighv1-5 -3.35 0.024434919 
Gpr63 -2.44 0.038541457 
Igkv6-23 2.03 3.13E-05 
Cyr61 -1.83 6.56E-07 
Ighv8-5 1.82 0.001789717 
Nr4a1 -1.74 2.69E-10 
Dusp1 -1.39 1.27E-07 
Fos -1.36 1.02E-06 
Egr1 -1.10 1.19E-06 
Sik1 -0.97 3.69E-05 
Klf2 -0.90 0.017155274 
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Table S3. 
DEseq analysis of exact sequence variants (ESVs) differing in abundance according to 
mouse genotype in either feces or the lumen and mucus of the ileum and colon of ex-germ-
free mice. 
Enriched 
in: 
Sample type log2(fold-
change) 
Adjusted p-
value 
Best taxonomic 
assignment 
BALB/c mucus and lumen -8.634412444 0.000312846 Mollicutes RF39 
BALB/c mucus and lumen -3.905449189 0.000551256 Bacteroides fragilis 
BALB/c mucus and lumen -3.519511063 0.001725039 Lachnospiraceae 
IgA-/- mucus and lumen 2.821434619 0.001983777 Ruminococcus 
IgA-/- mucus and lumen 5.7119259 0.001221637 Clostridiales 
IgA-/- mucus and lumen 5.039308072 2.76E-05 Lachnospiraceae 
IgA-/- mucus and lumen 3.467202384 2.76E-05 Ruminococcus gnavus 
IgA-/- mucus and lumen 7.097420438 4.84E-08 Alphaproteobacteria 
BD7-3 
     
BALB/c feces -24.05671228 3.37E-23 Mollicutes RF39 
BALB/c feces -7.354148271 1.01E-06 Lachnospiraceae 
BALB/c feces -5.70390907 0.00543052 Coprococcus 
IgA-/- feces 4.450515436 0.008991039 Clostridiales 
IgA-/- feces 2.283274756 0.001376256 Adlercreutzia 
IgA-/- feces 8.12403428 2.37E-08 Alphaproteobacteria 
BD7-3 
IgA-/- feces 20.67955327 3.84E-20 Clostridiales 
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Table S4. 
Bacterial strains and plasmids used in this study.   
Strain / Plasmid Description Source 
Bacteroides fragilis 
NCTC9343 
Type strain, parent for all mutants in this study ATCC 
Bacteroides 
thetaiotaomicron 
ATCC 29148 
Type strain ATCC 
Bacteroides vulgatus 
ATCC8482 
Type strain ATCC 
B. fragilis ∆ccf An in-frame deletion within the operon containing 
ccfC, ccfD, and ccfE (BF3581-79) 
(26) 
B. fragilis ∆PSC An in-frame deletion of non-regulatory genes in the 
PSC locus (BF1011-26) 
This study 
B. fragilis ∆PSB An in-frame deletion of non-regulatory genes in the 
PSB locus (BF1895-1914) 
(67) 
B. fragilis ∆PSB/C ∆PSC mutation made in a ∆PSB background This study 
pFD340 Escherichia coli (Carbenicillin) / Bacteroides 
(Erythromycin) shuttle vector 
(68) 
pFD340-ccfA Overexpression of the sigma factor ccfA using the 
IS4351 promoter on pFD340 
This study 
pFD340-chlor Marker plasmid for mouse colonization experiments 
(Erythromycin, Chloramphenicol) 
(26) 
pFD340-tet Marker plasmid for mouse colonization experiments 
(Erythromycin, Tetracycline) 
(26) 
pNJR6 Suicide plasmid for allelic exchange (Kanamycin for 
E. coli, Erythromycin for B. fragilis) 
(69) 
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Table S5. 
Primers used for cloning, generating mutants, and qPCR.   
Primer Sequence Purpose Source 
∆PSC 
primer-1 
GTGGATCCAAATGCGTTGCTTTTGCTTT Left flank PSC 5’ This study 
∆PSC 
primer-2 
AAACCATGGTTCGAAATCGTTTTGCTTC
A 
Left flank PSC 3’ This study 
∆PSC 
primer-3 
GATTTCGAACCATGGTTTATGCTGGCTT
T 
Right flank PSC 
5’ 
This study 
∆PSC 
primer-4 
TTGGATCCAACACTACGCCTACCCGATG Right flank PSC 
3’ 
This study 
PSC WT 
1 
GGAGGATGTTTGAATTGGTGG PSC WT check 5’ This study 
PSC WT 
2 
CCCGCTTAATGCCCTAAAAT PSC WT check 3’ This study 
PSC KO 
1 
GGAGGATGTTTGAATTGGTGG PSC KO check 5’ This study 
PSC KO 
2 
TATCCTGATGTTCTGCTTTTCCG PSC KO check 3’ This study 
ccfA 1 AAGGATCCTGCGCAACTGATATTGTTAG
AA 
ccfA (BF3583) 
cloning 5’ 
This study 
ccfA 2 AAGAGCTCCGAAATCTACTCAGTGTAAA
TGGA 
ccfA (BF3583) 
cloning 3’ 
This study 
q. gyrB 1 GTGAATGAGGACGGCAGTTT qPCR gyrase This study 
q. gyrB 2 CTCGATGGGGATGTTTTGTT qPCR gyrase This study 
q. PSA 1 TTGTATCCGCAAGGGAGAGA qPCR PSA This study 
q. PSA 2 CGCTCCATACTGCCCATATT qPCR PSA This study 
q. PSB 1 GCTTTTGGCTTAATGCTTGTTGG qPCR PSB This study 
q. PSB 2 GCCTAGAAGTACAATTAGCCCGA qPCR PSB This study 
q. PSC 1 TGTTTGGTGGCTGCTACTTG qPCR PSC This study 
q. PSC 2 AGGTGAAGTTTGAAGCCAAGG qPCR PSC This study 
q. PSD 1 CAATTTGGGAGGTGCGTTGT qPCR PSD This study 
q. PSD 2 ACGACCAATCCAAAACCCCA qPCR PSD This study 
q. PSE 1 TGCCTCCCTGTTGGTGAAAA qPCR PSE This study 
q. PSE 2 AGCGTTAGCCAAACTCCGTA qPCR PSE This study 
q. PSF 1 TTCTATCGTTCAGCGTGCGA qPCR PSF This study 
q. PSF 2 TGCCCATACGCCAAATCCTT qPCR PSF This study 
q. PSG 1 CAAGTACACCTGTCAGTAGTTTGC qPCR PSG This study 
q. PSG 2 GCAACTTCCAATTCCTAACAAAAGA qPCR PSG This study 
q. PSH 1 GGAAAACAGTCGGAATGGCTC qPCR PSH This study 
q. PSH 2 TTCCACACACGCAGACACAA qPCR PSH This study 
q. ccfA 1 GGAATTTGCATGACACTTAT qPCR ccfA (26) 
q. ccfA 2 CTGAGAGGTTTCATCTTCTG qPCR ccfA (26) 
q. ccfB 1 AGTGTCCCCACTTCATCGTC qPCR ccfB (26) 
q. ccfB 2 TGAAACTTTTGCCGGAGAAT qPCR ccfB (26) 
q. ccfC 1 GATGAACTGATAGCCCATTA qPCR ccfC (26) 
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q. ccfC 2 TAGCGATGACTAAAGGTGTT qPCR ccfC (26) 
q. ccfD 1 CGGTTATATGCTTTTCAAAC qPCR ccfD (26) 
q. ccfD 2 CAAATAGAAATCTGCCAAAC qPCR ccfD (26) 
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Materials and Methods 
Bacterial strains, media, and plasmids 
Bacteroides fragilis NCTC9343 was grown in Brain Heart Infusion (BD) supplemented 
with 5 µg/ml hemin (Frontier Scientific) and 5 µg/ml vitamin K1 (Sigma) in an anaerobic 
atmosphere of 80% nitrogen, 10% carbon dioxide, and 10% hydrogen. For selection, 200 
µg/ml gentamicin, 10 µg/ml erythromycin, 10 µg/ml chloramphenicol, or 2 µg/ml 
tetracycline was added. For in vivo studies, B. fragilis carried a marker plasmid pFD340-
Chlor or pFD340-Tet which confer resistance to chloramphenicol and tetracycline, 
respectively, allowing identification of multiple strains within an animal without affecting 
their fitness (26). PSC was deleted by allelic exchange with a suicide plasmid (pNJR6) as 
previously described (26). Details for all strains and plasmids are listed in Table S4 and 
primers for cloning in Table S5. 
Mice 
All mouse experiments were performed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals using protocols approved by the Institutional Animal Care 
and Use Committee at the California Institute of Technology. Swiss Webster, C57BL/6, 
Rag1-/-, and BALB/c mice from Taconic Farms and BALB/c IgA-/- mice from the Baylor 
College of Medicine were C-section rederived germ-free and bred in flexible film isolators. 
Unless specifically stated, Swiss Webster mice were used for all experiments due to ease 
of breeding in gnotobiotic conditions. Eight-week-old germ-free mice were transferred to 
autoclaved microisolator cages supplied with autoclaved chow (LabDiet 5010) and 
autoclaved water containing 10µg/ml erythromycin (to select for marker plasmids) and 
100µg/ml gentamicin (to which Bacteroides are naturally resistant). Mice were mono-
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colonized by a single oral gavage of 10^8 CFU in 100µl of HBSS with 1.5% sodium 
bicarbonate and maintained for at least 4 weeks prior to any imaging, mucosal plating, gene 
expression, or colonization experiments. Colonization was confirmed for all mice and 
monitored over time using freshly collected fecal samples. Feces were weighed, mashed 
and vortexed in 1 ml BHI, spun at 400 g for 1 minute to pellet debris, and then diluted for 
CFU plating. 
 For depletion of B cells, 8-week-old germ-free Swiss Webster mice were injected 
intraperitoneally with 250 µg of monoclonal anti-mouse CD20 antibody (clone 5D2 from 
Genentech) or 250 µg of an isotype control (IgG2a from Bio X Cell). One week later, mice 
were mono-colonized. One week after that, the mice were given a second identical antibody 
injection. Four weeks after mono-colonization, the mice were used for horizontal 
transmission experiments. 
Horizontal transmission and sequential gavage colonization assays 
For horizontal transmission experiments, pairs of mono-colonized female mice were 
cohoused in a new autoclaved cage for 4 hours during the day (16 hours overnight for 
BALB/c mice, which exhibited a higher threshold for invasion), then individually housed 
in new autoclaved cages. For each experiment, the antibiotic resistance markers (Tet and 
Chlor) were swapped for half the animals (for example: WT-Tet vs. ∆ccf-Chlor, and then 
WT-Chlor vs. ∆ccf-Tet) to ensure that the difference in horizontal transmission was due to 
the bacterial or mouse genotype and not due to the different antibiotic resistance markers. 
The same assay was performed in specific pathogen free (SPF) BALBc mice by first 
treating with ciprofloxacin and metronidazole as described previously (26) to allow 
colonization with B. fragilis. For sequential gavage experiments, mice mono-colonized for 
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three weeks were gavaged with 108 CFU of the challenge strain in HBSS with 1.5% sodium 
bicarbonate and subsequently single-housed. The community-level comparison of BALB/c 
mice (Fig. 4H and I) was made by gavaging 8-10 week-old mice with 100 µl cecal contents 
(donors: 8 week-old Swiss Webster mice delivered from Taconic, 2 male and 2 female 
cecums dissected and pooled) homogenized to saturation in HBSS with 1.5% sodium 
bicarbonate. Mucus and lumen samples were collected 5 weeks after colonization. 
Sample preparation for electron microscopy 
A 1 cm portion of ascending colon from mono-colonized mice was excised and 
immediately fixed with an ice-cold solution of 3% glutaraldehyde, 1% paraformaldehyde, 
5% sucrose in 0.1 M sodium cacodylate trihydrate, without flushing of the intestinal 
contents.  Tissues were prefixed for 1 hour at 4°C, then transferred to a petri dish containing 
5% sucrose in 0.1 M cacodylate buffer.  Tissues were cut into ~1-2 mm3 blocks with a #11 
scalpel and placed into brass planchettes (Type A; Ted Pella, Inc., Redding, CA), prefilled 
with cacodylate buffer containing 10% Ficoll (70 kD, Sigma-Aldrich) which serves as an 
extracellular cryoprotectant.  Excess buffer was removed with Whatman filter paper and 
the sample covered with a Type B brass planchette.  Samples were ultra-rapidly frozen 
with a HPM-010 high-pressure freezing machine (Leica Microsystems, Vienna Austria), 
then transferred immediately under liquid nitrogen to cryotubes (Nunc) containing a frozen 
solution of 2.5% osmium tetroxide, 0.05% uranyl acetate in acetone.  The tubes were 
loaded into a AFS-2 freeze-substitution machine (Leica Microsystems) precooled to -
100°C.  Samples were processed at -90°C for 72 hours, warmed over 12 hours to -20°C, 
held at that temperature for 6-10 hours, and then warmed to 4°C for 1 hour.  The fixative 
was removed and the samples rinsed four times with cold acetone, infiltrated into Epon-
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Araldite resin (Electron Microscopy Sciences, Port Washington PA), and flat-embedded 
between two Teflon-coated glass slides.  Resin was polymerized at 60°C for 48 hours. 
Electron microscopy and dual-axis tomography 
Flat-embedded colon samples were observed with a stereo dissecting microscope to 
ascertain preservation quality and select appropriate regions for EM study.  These were 
extracted with a microsurgical scalpel and glued to the tips of plastic sectioning stubs.  
Semi-thick (300 or 400 nm) serial sections were cut with a UC6 ultramicrotome (Leica 
Microsystems) using a diamond knife (Diatome, Ltd. Switzerland).  Sections were placed 
onto Formvar-coated copper-rhodium 1 mm slot grids (Electron Microscopy Sciences) and 
stained with 3% uranyl acetate and lead citrate.  Gold beads (10 nm) were placed on both 
surfaces of the grid to serve as fiducial markers for subsequent image alignment. Grids 
were placed in a dual-axis tomography holder (Model 2040, E.A. Fischione Instruments, 
Export PA) and imaged with a Tecnai TF30ST-FEG transmission electron microscope (300 
KeV; FEI Company/ThermoFisher Scientific, Hillsboro OR) equipped with an XP1000 2k 
x 2k CCD camera (Gatan, Inc. Pleasanton CA). Tomographic tilt-series and large-area 
montaged overviews were acquired automatically using the SerialEM software package 
(49).  For tomography, samples were tilted +/- 64° and images collected at 1° intervals. 
The grid was then rotated 90° and a similar series taken about the orthogonal axis. 
Tomographic data was calculated, analyzed, and modeled using the IMOD software 
package (50, 51). For quantification of epithelial associated bacteria (Fig. 1F and 4J), 
sections were surveyed until a bacterium on the apical epithelial surface was identified, 
and then a ~20 x 20 µm montaged projection image was acquired. Bacterial cells were 
identified by morphology and counted. About 1 mm length of epithelium was scanned per 
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mouse, including an area of around 20 µm from the apical epithelial surface into the mucus. 
For measurement of the capsule thickness (Fig. 1I), the distance between the outer 
membrane and edge of the electron-dense capsule layer was measured in tomograms. Ten 
different measurement sites on the same cell were averaged for each cell. 
Mucosal scraping for CFU quantification or sequencing analysis 
The ascending colon was dissected and cut open longitudinally. Lumen content was 
removed, and the flat tissue was washed with HBSS until no feces could be observed. A 1 
cm length of the tissue was cut, making an approximately 1 cm x 1 cm square of flat tissue. 
Mucus was removed from the epithelial surface by holding one corner of the tissue and 
using light pressure with a sterile plastic 1.8 cm cell scraper (BD Falcon). For sequencing 
analysis, mucus was frozen at this point. For CFU quantification, the mucus was moved 
into a 2 ml screw cap tube with 1.4 mm ceramic beads (Lysing Matrix D, MP Biomedicals) 
and 1 ml of HBSS and bead beat on medium for 1 minute to homogenize the mucus. This 
homogenate was diluted for CFU plating. 
RNA isolation 
Pelleted mid-log bacterial cultures, freshly harvested colon lumen contents, or whole colon 
tissue were immediately lysed by bead-beating in a mixture of 500 µl buffer (0.2 M NaCl 
and 20 mM EDTA), 210 µl 20% SDS, and 500 µl phenol, chloroform, and isoamyl alcohol 
(Ambion AM9720). The aqueous phase was separated by centrifugation and moved to a 
new tube for a second extraction with phenol, chloroform, and isoamyl alcohol. Then, 50 
µl of 3 M sodium acetate and 500 µl of cold ethanol were mixed in to the aqueous fraction 
and placed on ice for 20 minutes. RNA was pelleted and washed once with cold 70% 
ethanol, and then resuspended in 100 µl water. RNA was further purified using the Qiagen 
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RNeasy mini kit according to the manufacturer instructions. DNA was removed using 
Turbo DNase (Ambion AM2238) for one hour at 37 C before applying to a second Qiagen 
RNeasy column, including an on-column Qiagen RNase-free DNase digest. 
qRT-PCR 
First-strand cDNA synthesis from total RNA was achieved using the manufacturer’s 
instructions for the iScript cDNA synthesis kit (Bio-Rad). Reactions were run on an ABI 
PRISM 7900HT Fast Real-Time PCR System (Applied Biosystems) with Power SYBR 
Green PCR Master Mix (Applied Biosystems). Relative quantification was performed 
using the ∆∆Ct method with gyrB (DNA gyrase) as the housekeeping control gene. The 
mean Ct value from 3 technical replicates was used for each biological replicate. Primers 
are listed in Table S5. 
RNAseq 
For bacterial RNAseq (Fig. 2A), 10 ml liquid cultures were harvest at mid-log phase and 
total RNA was isolated as described above (RNA isolation). Libraries were prepared using 
NEBNext Ultra RNA Library Prep Kit for Illumina (NEB E7530) according to the 
manufacturer’s instructions and sequenced on an Illumina HiSeq2500 in single read rapid 
run mode with single-end 50 bp reads. For each sample, at least 2.5 million reads mapped 
to protein-coding genes. The bacterial RNAseq analysis package Rockhopper (52) was 
used for quality filtering, mapping, and differential expression analysis. 
 
For mouse RNAseq (Fig. 3A), a 1 cm length of opened and washed ascending colon tissue 
was prepped for total RNA as described above (RNA isolation). Ribosomal RNA was 
depleted using a Ribo-Zero Magnetic Gold Epidemiology Kit (Epicentre/Illumina). 
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Sequencing was done on an Illumina HiSeq2500 to produce 101-bp paired-end reads. 
Reads were trimmed with a Phred quality score cut-off of 20 using fastq_quality_trimmer 
from the FASTX toolkit, version 0.0.13 (http://hannonlab.cshl.edu/fastx_toolkit/). Reads 
shorter than 20 bp after adaptor and poly(A)-trimming were discarded. Trimmed reads 
were aligned to the mouse genome (build GRCm38.p4) by STAR (53), read counts were 
quantified using HTseq (54), and differentially expressed genes were identified using 
edgeR (55). 
Bacterial flow cytometry 
Fresh fecal pellets were mashed and vortexed in 1 ml of HBSS per 100 mg feces. Large 
debris was removed by centrifugation at 400 x g for 5 minutes. Supernatants, containing 
fecal bacteria, were diluted to 106 CFU per well in 96-well v-bottom plates, washed with 
HBSS, and stained with a monoclonal rat anti-mouse IgA conjugated to PE (eBioscience 
clone mA-6E1) or monoclonal rat anti-mouse IgM conjugated to PE (Biolegend clone 
RMM-1) at 1:250 and SYTO 9 nuclear stain (Molecular Probes) at 1:1000. After washing 
twice with HBSS, stained bacteria were analyzed on a MACSQuant VYB (Miltenyi). Data 
were analyzed using FlowJo. 
 For IgA affinity studies, IgA was extracted from fresh fecal samples by mashing 
and vortexing in 1 ml HBSS per 100 mg feces, then removing the insoluble fraction by 
centrifuging at 16,000 x g for 10 minutes at 4 C, and collecting the supernatant containing 
soluble IgA. The pellet was resuspended in the same volume for a second extraction. The 
combined supernatant was then sterile filtered, heat inactivated at 56 C for 30 minutes, and 
then stored at 4 C for up to 1 month (degradation was not observed by ELISA in this 
timeframe). IgA concentrations were measured using a Ready-SET-Go mouse IgA ELISA 
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kit (eBioscience) according to the manufacturers protocol. Binding assays were performed 
on fecal-derived bacteria from mono-colonized Rag1-/- mice so that the bacteria were in 
vivo-adapted (in which ccf is induced and the thick capsule is formed), but IgA-free 
(because Rag1-/- mice do not make antibody). 106 CFU per well in 96-well plates was 
incubated on a shaker with 200 µl IgA at a concentration of 1 µg / ml for 30 minutes and 
then stained for flow cytometry. 
Western blot 
Fresh fecal pellets from Rag1-/- mice were mashed and vortexed in 1 ml of BHI per 100 
mg feces. Large debris was removed by centrifugation at 400 x g for 5 minutes. This 
supernatant or late-log cultures of bacteria were pelleted at 8,000 g and resuspended at 10X 
concentration in BHI. The concentrate was mixed 1:1 with 2X Laemmli sample buffer and 
boiled for 10 minutes to lyse bacteria. 20 µl of lysate (108 CFU) was loaded per well in 
tris-glycine gels with a 4-20% polyacrylamide gradient (Novex WedgeWell), ran in a tris-
glycine buffer with 0.1% SDS (Bio-Rad). Gels were transferred at 4 C overnight to a PVDF 
membrane in the same buffer supplemented with 20% methanol. PVDF blots were blocked 
for 1 hour in PBS-T (PBS with 0.1% Tween20) with 5% powdered milk, washed with PBS-
T, and then stained with IgA, extracted from feces as described above, at a final 
concentration of 0.1 µg / ml in PBS-T with 2.5% powdered milk for 2 hours. Blots were 
washed four times with PBS-T, stained with an HRP goat anti-mouse IgA (Southern 
Biotech 1040-05) diluted 1:1000 in PBS-T with 2.5% powdered milk for 1 hour, washed 
four times again, and then developed with a Clarity western ECL substrate (Bio-Rad). 
Tissue-cultured epithelial cell adherence assay 
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Intestinal epithelial cell lines HT29, HT29-MTX, and Caco-2 were maintained in high 
glucose DMEM with 4 mM L-glutamine, 4.5 g / L glucose (HyClone), supplemented with 
10% fetal bovine serum (FBS) (Gibco), and penicillin-streptomycin solution (Corning). 
Cells were seeded in flat 96-well plates at a density of 25,000 cells per well and then grown 
for seven days past confluence to allow production of mucus. IgA was extracted and bound 
to fecal-derived bacteria from mono-colonized Rag1-/- mice so that the bacteria were in 
vivo-adapted but IgA-free as described above (Bacterial flow cytometry for IgA coating 
and affinity). IgA-coated bacteria were pelleted and resuspended in high-glucose DMEM 
without antibiotics or FBS. Epithelial cells were washed once with HBSS and then 
incubated with 106 coated bacteria for 2 hours at 37 C in an anaerobic atmosphere of 80% 
nitrogen, 10% carbon dioxide, and 10% hydrogen to allow adherence of bacteria. Bacterial 
growth was not observed within this timeframe either on epithelial cells or in media alone. 
Wells were washed twice with 200 µl HBSS to remove unbound bacteria, and then 
trypsinized with 50 µl of 0.05% trypsin in HBSS (Corning) for 20 minutes at 37 C to 
disassociate epithelial cells. Then 50 µl of BHI was added and cells were vigorously 
resuspended before dilution plating for CFU. Fraction bound was calculated as the output 
CFU / input CFU. For all epithelial cell adherence assays, the average of 4 technical 
replicates (4 separate binding reactions with the same IgA and bacteria on 4 wells of cells) 
is reported for each biological replicate. 
B cell flow cytometry 
Cells were isolated from the peritoneum, mesenteric lymph nodes, and colon tissues. The 
peritoneal space was injected with PBS and massaged for thirty seconds to suspend cells. 
Mesenteric lymph nodes were dissected and single cell suspensions were obtained by 
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grinding tissues through a 100 µm cell strainer. Colonic lamina propria lymphocytes were 
isolated by first flushing lumen contents away with PBS, and removing the longitudinal 
and circular muscle layers of the colon by micro-dissection. The remaining tissue was 
incubated in 1 mg / mL Collagenase II (Dibco) for 1 hour and then cells were filtered 
through a 100 µm cell strainer. Cells were spun down, resuspended and separated by a 
40%/80% (v/v) Percoll (GE Healthcare) density gradient. All cells were washed in 
complete RPMI buffer, allowed to rest at 37 C for at least 1 hour in a 5 % CO2 tissue culture 
incubator, and incubated in 5% mouse serum for 15 minutes before proceeding to staining 
for flow cytometry. Cells were stained with a LIVE/DEAD fixable Violet dye (Life 
Technologies), FITC-conjugated B220 antibody (eBioscience clone RA3-6B2), and 
PerCP-Cy5.5-conjugated CD3e antibody (eBioscience clone 145-2C11) for 20 minutes at 
4 C. Cells were washed in HBSS with 1% BSA and fixed in 2% PFA prior to acquisition 
on a MACSQuant Analyzer (Miltenyi). Data were analyzed using FlowJo. 
Sorting IgA-bound bacteria for sequencing 
This method was carried out as previously described (35). Two fecal pellets were mashed 
and resuspended in 1 ml PBS with 0.5% BSA (this buffer used throughout the protocol). 
The homogenate was centrifuged at 400 g for 5 minutes to remove debris, and the 
supernatant was passed through a 30 µm filter. Bacteria were pelleted by centrifugation at 
8000 g for 5 minutes and resuspended in 1 ml buffer plus 35 µl of anti-IgA PE (eBioscience 
clone mA-6E1) and stained for 20 minutes at 4 C. Stained bacteria were pelleted, washed 
once, then resuspended in 1 ml buffer plus 100 µl ultrapure anti-PE magnetic beads 
(Miltenyi) and incubated for 15 minutes at 4 C. Bead-bound, stained bacteria were pelleted 
and resuspended in 500 µl buffer and then run over an MS column (Miltenyi) on an 
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OctoMACS separator (Miltenyi). Bound bacteria were eluted and re-loaded on the column 
three times to further purify. 
16S amplicon sequencing 
DNA was extracted from tissue scrapings, fecal samples, and IgA-sorted bacterial pellets 
using the Qiagen PowerMag Soil extraction kit and a ThermoFisher KingFisher magnetic 
bead purification robot. Extracted DNA was amplified and sequenced as in Caporaso et al 
(56). Briefly, the V4 region of the 16S ribosomal RNA gene was amplified in triplicate 
using the 515F/805R primers from the Earth Microbiome Project (57) and amplicons 
pooled and sequenced on an Illumina MiSeq instrument. Sequences were uploaded to the 
Qiita analysis platform for demultiplexing and primary data processing 
(https://qiita.ucsd.edu/). Exact sequence variants (ESVs) were identified and chimeric 
sequences removed using the Deblur plugin in Qiita (58). For phylogenetic analyses, ESVs 
were inserted into the GreenGenes reference phylogeny (release 13_8, (59))using SEPP 
(60). Taxonomy was assigned per ESV according to its placement in the GreenGenes 
phylogeny using the fragment-insertion pluging in Qiime 2 v2017-12 (https://qiime2.org). 
Samples yielding less than 1000 Deblurred sequences were excluded from subsequent 
analysis. 
16S diversity analyses 
We used the Galaxy implementation LEfSe (61) to identify taxonomic groups that were 
significantly enriched (LDA effect size ≥ 2) in bacterial pellets purified using anti-IgA 
antibodies, coding pellet sort status as a class and mouse sex as subclass and normalizing 
to 10^6 counts per sample. To identify specific ESVs differentially represented in tissues 
or feces of BALB/c and BALB/c IgA-/- mice, we used the DESeq2 (62) in R (63), adding 
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a pseudocount of 1 to all ESVs and fitting models using a negative binomial distribution. 
Analyses of microbial community beta-diversity were performed using the Weighted 
UniFrac metric (64) calculated from count tables rarefied to 1000 sequences in Qiime2. 
Principle Coordinate Analyses and Adonis tests of group differences in central tendency 
(65) were performed in the Vegan package in R (66). 
Statistical methods 
All bar graphs show mean values with standard error of measurement. Log-scale line 
graphs for horizontal transmission and sequential gavage assays show the geometric mean 
and 95% confidence interval. Post-hoc corrections for multiple comparisons were the 
Tukey method when comparing all groups with each other and Sidak for other types of 
comparisons. 
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ABSTRACT 
Gut microbiota inhabit a variety of microenvironments within the gastrointestinal tract, and 
a subset of this community specializes in colonizing the epithelial surface. Transcriptomic 
analysis of bacteria within host-associated niches is challenging due to the overabundance of 
host RNA. We applied hybrid selection RNA-seq to compare the transcriptome of 
Bacteroides fragilis in the colon lumen, mucus and tissue of mono-colonized mice. Hybrid 
selection increased reads mapping to the B. fragilis genome by 48 and 154-fold in mucus and 
tissue, allowing for high fidelity comparisons across sample sites. In the mucus and tissue, 
B. fragilis up-regulated many genes involved in protein synthesis, indicating these bacteria 
are active and thriving in the mucosal niche. Rather than broad changes in metabolic 
pathways, a specific sulfatase and glycanase were highly induced in mucus and tissue. 
Mutants in these individual genes exhibited a mucus-specific defect in colonization of the 
mouse colon, which was disadvantageous during competitive colonization experiments. 
Furthermore, the mucosal glycanase was required for B. fragilis-mediated 
immunomodulation and protection from colitis. Therefore, colonization of the colon mucus 
is mutually beneficial for this bacterial symbiont and its mammalian host. 
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INTRODUCTION 
The mammalian gastrointestinal tract hosts a microscopic ecosystem of bacteria, protists, 
fungi, and viruses. For the host, this community is critical to digestion, nutrient extraction, 
and inhibition of pathogen colonization. Though most microbiome profiling relies on 
homogenized fecal samples, the gut community is spatially structured in important ways1. 
Notably, mucus secreted from intestinal goblet cells provides both a physical barrier that 
limits microbial colonization of the intestinal surface2 and a carbon/energy source for the 
indigenous microbiome3-5. Accordingly, the mucus and lumen of the intestines exhibit 
distinct community compositions6-9. Some bacteria also directly associate with the intestinal 
surface, such as segmented filamentous bacteria10,11, adherent Lactobacillus12, and a 
community of crypt-resident bacteria13-15. Generally, studying the relevance of spatial 
structure is a challenge because of the dynamic nature of the gut and complexity of the 
community. Imaging studies can provide valuable snapshots of gut organization16,17, but the 
functional relevance of localization is difficult to infer. Mechanisms and implications of 
mucosal colonization by indigenous gut bacterial species remain relatively poorly defined. 
 
Attempts to investigate bacterial transcriptomics in host tissues or mucus are complicated by 
the miniscule quantity of bacterial RNA present compared to host RNA. Separating bacterial 
cells from host cells can be done by size at the cellular level, prior to RNA extraction, but 
this risks bacterial stress responses during the procedure. As typical bacterial mRNAs have 
in vivo half-lives of just a few minutes18, rapid dissection and RNA stabilization is critical to 
high fidelity transcriptomics. This favors an alternative strategy: to separate bacterial 
transcripts at the molecular level, following nucleic acid extraction. Here we used hybrid 
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selection to enrich bacterial cDNA out of total cDNA preparations using biotinylated probes 
complementary to the whole bacterial genome. Host cDNA can then be washed away, 
allowing captured bacterial cDNA to be eluted and amplified for sequencing (Fig. 1a). This 
method was originally developed for the purification of re-sequencing targets in the human 
genome19 and was then adapted to enrich pathogen DNA in clinical samples dominated by 
human genetic material20,21. We used a unified protocol to isolate total RNA from proximal 
colon lumen, mucus, and tissue samples from gnotobiotic mice mono-colonized with 
Bacteroides fragilis (Fig. 1a). B. fragilis is a mammalian gut symbiont that binds mucin22, 
penetrates colonic crypts of Lieberkuhn in mice23, and is enriched in the mucosal population 
in primates8. 
 
RESULTS 
Hybrid selection enriches bacterial RNA is mucus and tissue samples 
To test this enrichment method on murine gut samples, we performed RNA sequencing 
(RNA-seq) with and without hybrid selection (Supplementary Table 1). Without hybrid 
selection, bacterial RNA represented 50% of the total RNA in the lumen, but only 0.6% and 
0.1% of total RNA in mucus and tissue samples, respectively (Fig. 1b). After hybrid 
selection, we observed a reduction in unaligned reads and reads mapping to the mouse 
genome, with a corresponding increase in reads mapping to the B. fragilis genome 
(Supplementary Table 1). The percentage of total reads mapping to the B. fragilis genome 
increased 48 and 154-fold in the mucus and tissue, respectively (Figure 1b). This striking 
enrichment resulted in three times more coverage over B. fragilis genes in the mucus sample, 
and almost ten times more gene coverage in tissue samples (Figure 1c). Gene expression 
 118 
levels between the hybrid selected and non-hybrid selected samples were highly correlated 
within sample sites (Supplementary Fig. 1), indicating that the procedure did not globally 
skew the transcriptome.  
 
Hybrid selection also improved our ability to perform comparisons across 
microenvironments. Limited bacterial transcript coverage in the mucus and tissue without 
hybrid selection led to a large number of genes with near-zero expression levels (555 and 
1034, respectively, Figure 1d). For most of these, we were able to measure a higher 
expression value in the hybrid-selected samples (159 and 299 remained with near-zero 
expression values in mucus and tissue, respectively, after hybrid selection). Assuming that 
the majority of transcripts should be unchanged across sample sites, correlation of the more 
reliable lumen transcriptome with the host-associated samples can be used as a measure of 
fidelity. Hybrid selection substantially improved the correlation of gene expression levels 
between lumen and mucus as well as lumen and tissue (Figure 1d). As a result, hybrid 
selection greatly increased the number of genes identified in a differential expression analysis 
between different microenvironments (Figure 1e). This method greatly enriched bacterial 
transcripts in host-associated sample types without skewing the transcriptome, facilitating 
spatial comparisons within the gut. 
 
Differentially expressed genes between gut micro-environments 
We proceeded to analyze differentially expressed genes between lumen, mucus, and tissue 
samples with hybrid selection (Fig. 2, Supplementary Fig. 2). As compared to the lumen, in 
the mucus 26 genes were significantly up-regulated and 42 were down-regulated (Figure 2a, 
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Supplementary Table 2). Also compared to the lumen, in the tissue 52 genes were up-
regulated and 47 were down-regulated (Figure 2a, Supplementary Table 3). No genes had 
significantly different expression values between mucus and tissue. Of the differentially 
expressed genes, 37 changed in the same direction for both mucus and tissue, while 31 genes 
significantly changed only in mucus and 62 changed significantly only in tissue. We did not 
observe broad shifts in metabolic or other pathways, though the Pfam24 for glycosyl 
transferase group 1 was slightly overrepresented in the lumen (Supplementary Table 4). 
 
We examined genes down-regulated in the mucus and tissue to assess the relative behavior 
of B. fragilis in the fecal stream. A universal stress gene, uspA (BF2495), was more highly 
expressed in the lumen than mucus (Supplementary Table 2b). Interestingly, an adenine-
specific DNA methyltransferase (BF1252) was the most highly expressed in lumen 
compared to tissue (Fig. 2b). DNA methylation in bacteria is widespread and important for 
genome protection25. Furthermore, two bacterial histone-like proteins (BF3379, BF4220) 
were also more highly expressed in the lumen (Supplemental Tables 2b and 3b), which may 
also be involved in genome protection26. Compared to the mucus and tissue, the behavior of 
B. fragilis in the lumen points toward persistence rather than growth. 
 
Another one of the most down-regulated genes in mucus and tissue was the flippase 
transporter (BF0737) for Polysaccharide G (PSG) (Fig. 2b). Four other genes in the PSG 
biosynthesis locus were also significantly down-regulated during host association 
(Supplementary Fig. 2a, Supplementary Tables 2b and 3b), and the biosynthesis locus for 
PSG as a whole trended toward lumen enrichment (Supplementary Fig. 2c). A characteristic 
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feature of Bacteroides species is the presence of multiple biosynthesis loci for capsular 
polysaccharides. B. fragilis has 8 such loci, and its ability to switch between multiple 
capsules contributes to fitness in the gut27,28. But the other 7 capsular polysaccharide 
biosynthesis loci (PSA-PSF and PSH) were not differentially expressed. This suggests that 
PSG has a unique lumen-specific role in the physiology of B. fragilis. Taken together with 
the stress response and genome protection, perhaps this prepares the bacteria for survival 
outside of the host. 
 
The genes up-regulated in the mucus and tissue support the theory that B. fragilis is adapted 
to living on the intestinal surface. Though anaerobic, B. fragilis is actually well-equipped29 
to contend with reactive oxygen species emanating from the host9. Indeed, both subunits of 
alkyl hydroperoxide reductase (a reactive oxygen species resistance enzyme), ahpC 
(BF1210) and ahpF (BF1209)30, were induced in mucus and tissue (Fig. 2c, Supplementary 
Tables 2a and 3a). Interestingly, 14 tRNAs were up-regulated in the mucus and 26 in the 
tissue whereas no tRNAs were more highly expressed in the lumen (Supplementary Fig. 2c, 
Supplementary Tables 2a and 3a). Ribonuclease P (RNase P), the ribozyme that cleaves the 
precursor RNA on tRNAs to form mature tRNAs, was also up-regulated in both the mucus 
and tissue (Supplementary Fig. 2d). A number of ribosome-related genes were up-regulated 
in the tissue, including 30S and 50S subunits (Supplementary Fig. 2b, Supplementary Table 
3a). Collectively, this indicates that B. fragilis expands its capacity for protein synthesis in 
the mucus and tissue. 
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Rather than observing global metabolic shifts between microenvironments, we observed a 
small number of individual metabolic genes with spatially differentiated expression patterns. 
The two most up-regulated genes in host-associated samples (mucus and tissue) were 
BF3134, a glycanase (glycosyl hydrolase family 13), and BF3086, one of 17 sulfatases in the 
genome (Fig. 2b, Supplementary Fig. 2e). The induction of these enzymes is likely for the 
metabolism of mucosal glycans, which have unique structures and are often sulfated31. We 
would not have been able to confidently detect up-regulation of these two genes in the tissue 
samples without hybrid selection, as the average number of reads per sample without hybrid 
selection was only 14. 
 
We examined the conservation of these two genes across a set of 92 Bacteroides and 
Parabacteroides genomes (see Materials and Methods). The average pairwise nucleotide 
identity within the 13 B. fragilis BF3134 and BF3086 genes was 99.7% and 99.5%, 
respectively, while the average pairwise identity between the non-B. fragilis genomes in our 
dataset was 66% and 69%, respectively, indicating significant conservation within B. fragilis, 
but significant diversity outside of B. fragilis (Supplementary Fig. 3a). Interestingly, we 
found a matching 36 bp gapped motif (Supplementary Fig. 3b) upstream of both BF3086 and 
BF3134 which was conserved in 13 closely-related B. fragilis genomes upstream of 
orthologous genes (Supplementary Fig. 3a). Three “B. fragilis” genomes that did not have 
the motif upstream of orthologues for these two genes appeared to actually be different 
species (see “Motif scanning” methods). The conservation of these host-association genes 
across strains of B. fragilis motivated us to investigate their importance by making in-frame 
deletions of both genes. 
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BF3086 and BF3134 are mucosal colonization factors 
To assess the function of these enzymes, we compared growth of the BF3086 and BF3134 
mutants with wild-type B. fragilis in minimal media with defined carbon sources. All three 
strains showed similar growth profiles in several dietary polysaccharides (Supplementary 
Fig. 4a-c). Their growth was also similar in purified pig mucin (Supplementary Fig. 4d). We 
sought to more accurately model mucosal growth in vitro using bulk mucus from germ-free 
mice (see Methods). B. fragilis grew rapidly, but the BF3134 mutant saturated at a lower 
CFU / ml (Fig. 3a). Furthermore, while wild-type bacteria had a stable stationary phase, the 
BF3134 mutant entered a rapid death phase (Fig. 3a). The BF3086 mutant also exhibited a 
significantly faster death phase (Fig. 3a). This lack of persistence may reflect the mutants’ 
inability to use less accessible or lower abundance mucosal glycans that remain after log-
phase growth. Because growth in mucus is involved in association with the epithelial surface, 
we tested the ability of these mutants to adhere to mucus-producing tissue-cultured epithelial 
cells. While BF3086 exhibited a mild defect in adherence, BF3134 showed a dramatic defect 
(Fig. 3b). 
 
To test how these mucosal growth, persistence, and adherence phenotypes affect colonization 
in mice, we first mono-colonized mice with wild-type or mutant B. fragilis strains. All strains 
colonized mice stably and reached the same CFU level in feces (Fig. 3c), so we sacrificed 
the animals to assess spatial colonization differences. Although there were also equal 
amounts of bacteria in the colon lumen (Fig. 3d), both BF3086 and BF3134 mutants were 
defective in colonizing the colon mucus (Fig. 3e). We tested whether this difference in 
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mucosal colonization provides advantages to B. fragilis using a competitive colonization 
assay against wild-type bacteria. The BF3134 mutant had a dramatic defect, being eventually 
cleared from the animal (Fig. 4a). Consistent with the subtle in vitro phenotypes, the BF3086 
mutant did not show a competitive disadvantage (Fig. 4b). 
 
We have previously shown that B. fragilis mutants exhibiting defects in mucosal colonization 
are also unable to exclude competitors of the same species 23 (Chapter 2 of this thesis). In 
horizontal transmission assays, while mice colonized with wild-type B. fragilis (WT initial) 
remained essentially mono-colonized, mice initially colonized with either the BF3086 or 
BF3134 mutant were substantially colonized by the wild-type bacteria (Fig. 4c and 4d). This 
is consistent with a model whereby saturation of the mucosal niche prevents invasion by a 
foreign strain. The implication that animals would maintain long-term colonization by only 
a single strain of B. fragilis has been observed in longitudinal metagenomics studies in 
humans 32,33. 
 
BF3134 is required for B. fragilis protection from colitis 
While mucosal colonization has clear benefits for the bacteria, how this might affect the host 
is less obvious. B. fragilis protects mice from pathology in multiple models of colitis through 
the induction of anti-inflammatory IL-10 production in regulatory T cells (Tregs)34,35. 
Because this requires delivery of B. fragilis polysaccharide A to dendritic cells35, we 
hypothesized that mucosal colonization may be critical for its immunomodulatory effects. 
We tested this in mice mono-colonized with B. fragilis strains subjected to the DNBS model 
of experimentally-induced colitis. 
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Control mice were treated with ethanol (the carrier for DNBS) to assess any baseline 
differences between groups. The weight-loss associated with this control treatment was 
consistent whether mice were colonized with wild-type, BF3086 mutant, or BF3134 mutant 
strains (Supplementary Fig. 5a). The length of the colon was also consistent across these 
control groups (Supplementary Fig. 5b). When treated with DNBS, mice mono-colonized 
with wild-type B. fragilis begin to recover by day 3 (Fig. 5a). However, mice mono-colonized 
with the BF3134 mutant exhibited continued decline, having lost significantly more weight 
by day 3 (Fig. 5a). Accordingly, this group of mice had significantly shorter colon lengths 
(Fig. 5b), a hallmark of worsened disease. The BF3086 mutant, which had less dramatic 
phenotypes in vitro and in vivo, was more similar to wild-type in having a protective effect 
in the mice. 
 
We hypothesized that defective mucosal colonization led to a loss of B. fragilis anti-
inflammatory effects on Tregs34-36. To test this, we isolated T cells from mesenteric lymph 
nodes 3 days after inducing colitis. Mice mono-colonized with the BF3134 mutant had 
similar amounts of pro-inflammatory IL-17 producing Tregs (Fig. 5c) but significantly less 
anti-inflammatory IL-10 producing Tregs (Fig. 5d). This indicates B. fragilis glycanase 
BF3134-dependent mucosal colonization is required for the protective anti-inflammatory 
effect of the symbiont. 
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DISCUSSION 
Comparisons of bacterial behavior in micro-environments allows for a more sophisticated 
understanding of host-microbe interactions. Hybrid selection greatly improved our ability to 
assess transcriptomics of host-associated bacteria. Unlike Bacteroides thetaiotaomicron 6, B. 
fragilis did not broadly alter metabolic pathways along the radial axis of the gut. We found 
instead that B. fragilis deployed a specific set of mucosal colonization factors during host 
association, including a sulfatase (BF3086) and a critical mucosal glycanase (BF3134). 
Sulfatases were previously shown to be important for mucosal glycan foraging by B. 
thetaiotaomicron37. Though association with the intestinal surface may be treacherous for 
many bacteria, B. fragilis can tolerate oxygen29, is resistant to many antimicrobial peptides38, 
and benefits from immunoglobulin A binding (Chapter 2 of this thesis). During colitis, 
bacterial penetration of mucus is generally associated with pathology39-41, but here we found 
that mucosal colonization by B. fragilis was protective. We conclude that the localization of 
B. fragilis in the mucus layer is fundamental to its ecology as well as its immunomodulatory 
effects. 
  
 126 
 
Fig. 1 | Hybrid selection enriches for bacterial RNA in host-associated gut samples. a, 
Colon lumen, mucus, and tissue samples were collected from mice mono-colonized with B. 
fragilis. Whole genome baits were used to select B. fragilis RNA from total RNA 
preparations. b, Average RNA-seq reads mapping to the B. fragilis genome with and without 
hybrid selection. c, Average read coverage of B. fragilis genes. d, Correlation in gene 
expression between different sample sites was improved with hybrid selection. All genes are 
plotted. e, Hybrid selection increases the number of genes identified in differential expression 
analyses between sample sites. 
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Fig. 2 | B. fragilis gene expression across microenvironments in the colon a, Genes 
differentially expressed between the lumen and mucus (inner circle) and lumen and tissue 
(outer circle). Squares in the innermost ring indicate genes differentially expressed in both 
(orange) or only one of the two comparisons (grey). b, Fold change in expression for 
individual genes in mucus and tissue, with respect to the lumen. 
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Fig. 3 | BF3086 and BF3134 are mucosal colonization factors. a, Growth of B. fragilis 
and mutants in BF3086 and BF3134 in defined minimal media with mouse mucus from 
germ-free mice as the sole carbon source (Tukey 2-way ANOVA on log-transformed data, 
n = 4 where each n is a different preparation of mucus). b, Adherence of B. fragilis strains to 
mucus-producing, tissue-cultured Caco-2 epithelial cells (Tukey 2-way ANOVA, n = 4). c, 
Quantification of bacteria in feces one month after mono-colonization with indicated strains 
of B. fragilis (Tukey ANOVA, n = 6). These mice were sacrificed to quantify d, colon lumen 
and e, colon mucus colonization levels (Tukey ANOVA, n = 6) (all panels: * p < 0.05, ** p 
< 0.01, *** p < 0.001). 
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Fig. 4 | Competitive colonization phenotypes of BF3086 and BF3134. a, Germ-free mice 
were gavaged with a 1:1 mixture of 108 CFU each of wildtype and ∆BF3134 B. fragilis. 
Colonization of each strain was tracked using antibiotic resistance markers (Sidak 2-way 
ANOVA of log-transformed data, n = 4) b, The same 1:1 gavage experiment with wildtype 
and ∆BF3086 B. fragilis (Sidak 2-way ANOVA of log-transformed data, n = 4). c, Horizontal 
transmission between pairs of mice mono-colonized with either wild-type B. fragilis (WT 
initial) or ∆BF3134 (BF3134 initial). Two weeks after separating the mice, levels of initial 
and foreign strains are graphed (Tukey 2-way ANOVA of log-transformed data, n = 6). d, 
Horizontal transmission with wild-type and ∆BF3086-colonized mice (Tukey 2-way 
ANOVA of log-transformed data, n = 6) (all panels: * p < 0.05, ** p < 0.01, *** p < 0.001). 
  
 130 
 
Fig. 5 | Effect of mucosal colonization on colitis. a, Mice were mono-colonized with B. 
fragilis strains for one month before DNBS colitis induction. Body weight of the mice was 
measured every 24 hours and graphed as a percentage of their starting weight on day 0 
(Tukey ANOVA). b, 72 hours after induction mice were sacrificed and the length of the 
colon from rectum to the cecal junction was measured (Tukey 2-way ANOVA). c, Images. 
d, Scores. e, Lymphocytes isolated from mesenteric lymph nodes of mono-colonized, 
DNBS-induced mice were analyzed using flow cytometry. IL-17A-producing T cells 
quantified as a percent of total Foxp3+ regulatory T cells (Tukey ANOVA). f, IL-10-
producint T cells quantified as a percent of total Foxp3+ regulatory T cells (Tukey ANOVA) 
(all panels: n = 10, 9, 9, * p < 0.05, ** p < 0.01, *** p < 0.001). 
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Supplementary Figure 1 | Comparison of gene expression with and without hybrid 
selection. Each gene is represented by a single dot. a, The correlation coefficient between 
lumen samples is 0.99. b, The correlation coefficient between mucus samples is 0.96. c, The 
correlation coefficient between tissue samples is 0.98. 
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Supplementary Figure 2 | Differentially expressed genes in micro-environments. a, 
STRING54 analysis of genes more highly expressed in the lumen than tissue. The thickness 
of connecting lines indicates confidence in relationships between genes. b, Same analysis of 
genes more highly expressed in the tissue than lumen (tRNAs are not included). c-e, Fold 
change in expression for individual genes in mucus and tissue, with respect to the lumen with 
indicated genes highlighted. 
  
 133 
 
Supplementary Figure 3 | Conservation of BF3086, BF3134, and a potential regulatory 
motif. a, Phylogeny of 92 Bacteroides and Parabacteroides strains50 showing conservation 
of BF3086, BF3134, and the upstream motif in B. fragilis strains (teal box). The black 
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squares indicate the presence of the conserved upstream motif, using the GALM2Scan 
algorithm51. Black corresponds to a motif “match” (0-2 mismatches). Green and purple bar 
graphs indicate the percent protein sequence identity of orthologues to BF3086 and BF3134. 
b, Sequence of the conserved motif upstream of both genes. 
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Supplementary Figure 4 | Growth of B. fragilis in minimal defined media with various 
carbon sources. a, inulin. b, pullulan. c, mannan. d, pig mucin (n = 8 for all). 
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Supplementary Figure 5 | Vehicle control (ethanol)-treated mice for DNBS colitis 
experiment. a, Mice mono-colonized with indicated strains of B. fragilis for one month were 
treated with 50% ethanol, the vehicle control for DNBS colitis induction. Mice were weighed 
every 24 hours, graphed as a percentage of their weight at day 0 (Tukey 2-way ANOVA, n 
= 5, 4, 4). b, 72 hours after treatment the mice were sacrificed and the length of the colon 
was measured from rectum to the cecal junction (Tukey 2-way ANOVA, n = 5, 4, 4). 
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Supplementary Table 1 | RNA-seq read counts and mapping statistics. Average values 
of three replicates and standard deviations are indicated. 
  Sample Total RNA-
seq reads 
% Reads 
mapped to B. 
fragilis 
genome 
% Reads 
mapped to 
mouse 
genome 
% Reads 
unaligned 
Median of % 
read coverage 
over B. fragilis 
genes 
Without 
hybrid 
selection 
Lumen 30,037,711 ± 4,838,289 50.4 ± 7.3 19.5 ± 8.2 30 ± 2.42 100 ± 0.0 
Mucus 30,851,659 ± 380,774 0.6 ± 0.2 66.9 ± 2.1 32.5 ± 2.1 31.9 ± 8.5 
Tissue 30,284,943 ± 3,142,595 0.1 ± 0.0 67.1 ± 0.6 32.8 ± 0.6 8.3 ± 4.0 
With 
hybrid 
selection 
Lumen 33,719,927 ± 5,268,780 84 ± 7.0 11.9 ± 6.3 4.2 ± 0.7 100 ± 0.0 
Mucus 30,509,921 ± 2,638,387 28.6 ± 6.8 60.9 ± 6.0 10.5 ± 0.9 95 ± 4.3 
Tissue 31,786,088 ± 5,102,116 15.4 ± 3.2 71.2 ± 2.5 13.3 ± 0.7 79.1 ± 4.3 
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Supplementary Table 2a | Fold change and adjusted p-value (FDR) of genes most up-
regulated in mucus compared to lumen. 
old locus 
tag 
new locus tag log2(fold 
change) 
FDR Product Name 
BF3086 BF9343_RS14795 2.75 9.2E-17 sulfatase 
BF3134 BF9343_RS15035 2.22 1.8E-13 glycosyl hydrolase family 13 
BF2146 BF9343_RS10075 1.99 1.1E-02 5-amino-6-(5-phosphoribosylamino)uracil 
reductase 
BF1418 BF9343_RS06550 1.59 1.8E-02  !-galactosidase 
- BF9343_RS21640 1.56 3.9E-06 RNase P RNA component class A 
BF1209 BF9343_RS05605 1.46 1.3E-02 NADH dehydrogenase 
BF1158 BF9343_RS05365 1.44 1.3E-04  !-glucosidase 
BF1210 BF9343_RS05610 1.31 1.2E-03 alkyl hydroperoxide reductase 
BF3147 BF9343_RS15100 1.29 3.0E-04 LacI family transcriptional regulator 
BF1394 BF9343_RS06445 1.20 1.5E-04 RNA polymerase sigma factor 
BF1425 BF9343_RS06580 0.97 8.0E-03 membrane protein 
BF3146 BF9343_RS15095 0.85 2.7E-02 SusC/RagA family TonB-linked outer membrane 
protein 
tRNAs 
BFt38 BF9343_RS12180 1.55 8.6E-08 tRNA-Gly 
BFt41 BF9343_RS13845 1.53 1.6E-07 tRNA-Asp 
BFt07 BF9343_RS02255 1.53 6.9E-06 tRNA-Phe 
BFt37 BF9343_RS12175 1.52 1.4E-07 tRNA-Leu 
BFt42 BF9343_RS13850 1.46 3.3E-06 tRNA-Asp 
BFt13 BF9343_RS04120 1.45 5.1E-07 tRNA-Tyr 
BFt06 BF9343_RS02250 1.45 1.8E-05 tRNA-Pro 
BFt33 BF9343_RS12155 1.35 6.2E-06 tRNA-Gly 
BFt12 BF9343_RS04115 1.32 6.2E-06 tRNA-Gly 
BFt15 BF9343_RS05655 1.30 1.8E-02 tRNA-Ser 
BFt36 BF9343_RS12170 1.27 4.0E-05 tRNA-Leu 
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BFt23 BF9343_RS09900 1.17 1.1E-02 tRNA-Asp 
BFt34 BF9343_RS12160 1.04 7.0E-04 tRNA-Leu 
BFt35 BF9343_RS12165 0.99 3.3E-03 tRNA-Gly 
 
  
 140 
Supplementary Table 2b | Fold change and adjusted p-value (FDR) of genes most 
down-regulated in mucus compared to lumen. 
old 
locus 
tag 
new locus tag log2(fold 
change) 
FDR Product Name 
BF3278 BF9343_RS15800 -2.54 4.0E-06 hypothetical protein 
BF3296 BF9343_RS15895 -2.29 6.3E-05 hypothetical protein 
BF0737 BF9343_RS03450 -2.25 5.9E-10 Polysaccharide G (PSG) flippase 
BF0611 BF9343_RS02855 -2.01 1.1E-07 amino-terminal protease 
BF3276 BF9343_RS15795 -1.90 1.7E-03 recombinase 
BF3294 BF9343_RS15885 -1.88 6.5E-03 hypothetical protein 
BF0739 BF9343_RS03460 -1.83 9.3E-05 hypothetical protein 
BF2112 BF9343_RS09910 -1.82 3.2E-03 RNA-directed DNA polymerase 
BF0466 BF9343_RS21570 -1.81 4.9E-03 hypothetical protein 
BF2365 BF9343_RS11175 -1.74 4.0E-03 hypothetical protein 
BF1641 BF9343_RS07560 -1.73 2.8E-02 hypothetical protein 
BF2397 BF9343_RS11345 -1.71 1.3E-02 hypothetical protein 
BF0738 BF9343_RS03455 -1.68 1.8E-04 glycosyltransferase 
BF2266 BF9343_RS10670 -1.68 6.8E-03 hypothetical protein 
BF0632 BF9343_RS02940 -1.60 1.3E-02 biotin-[acetyl-CoA-carboxylase] synthetase 
BF1252 BF9343_RS05815 -1.57 1.5E-03 DNA methyltransferase 
BF2487 BF9343_RS11795 -1.56 4.7E-02 chloramphenicol acetyltransferase 
BF2371 BF9343_RS11205 -1.55 1.6E-02 hypothetical protein 
BF2785 BF9343_RS13330 -1.55 4.5E-02 N-acetylmuramoyl-L-alanine amidase 
BF3797 BF9343_RS18370 -1.55 1.9E-02 hypothetical protein 
BF0144 BF9343_RS00645 -1.54 1.3E-02 hypothetical protein 
BF0117 BF9343_RS00530 -1.53 8.0E-03 hypothetical protein 
BF3410 BF9343_RS16455 -1.53 1.3E-02 DNA-directed RNA polymerase sigma-70 factor 
BF3379 BF9343_RS16290 -1.49 6.5E-07 histone H1 
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BF1525 BF9343_RS07025 -1.48 4.0E-03 hypothetical protein 
BF1037 BF9343_RS04885 -1.46 2.7E-02 hypothetical protein 
BF1568 BF9343_RS07220 -1.44 4.6E-04 DNA-binding protein 
BF2917 BF9343_RS13960 -1.41 7.4E-03 hypothetical protein 
BF0742 BF9343_RS03475 -1.39 2.0E-03 capsular polysaccharide-like protein 
BF2943 BF9343_RS14090 -1.33 1.3E-02 anti-sigma factor 
BF4220 BF9343_RS20550 -1.33 1.2E-03 DNA-binding protein HU-beta 
BF3140 BF9343_RS15065 -1.29 3.6E-05 50S ribosomal protein L31 type B 
BF2104 BF9343_RS09865 -1.20 1.3E-02 membrane protein 
BF0033 BF9343_RS00165 -1.20 2.9E-02 hypothetical protein 
BF1640 BF9343_RS07555 -1.18 1.3E-02 hypothetical protein 
BF0615 BF9343_RS02870 -1.15 1.0E-03 hypothetical protein 
BF1168 BF9343_RS05415 -1.13 3.0E-04 hypothetical protein 
BF4025 BF9343_RS19545 -1.10 1.4E-02 30S ribosomal protein S21 
BF1509 BF9343_RS06955 -1.08 4.5E-02 hypothetical protein 
BF2495 BF9343_RS11850 -0.96 4.9E-03 universal stress protein 
BF1167 BF9343_RS05410 -0.88 8.0E-03 preprotein translocase subunit YajC 
BF4200 BF9343_RS20455 -0.79 2.8E-02 glycosyl transferase family 1 
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Supplementary Table 3a | Fold change and adjusted p-value (FDR) of the most up-
regulated genes in tissue compared to lumen. 
old locus 
tag 
new locus tag log2(fold 
change) 
FDR Product Name 
BF3086 BF9343_RS14795 3.67 1.9E-
38 
sulfatase 
BF3134 BF9343_RS15035 2.49 8.2E-
11 
glycosyl hydrolase family 13 
BF1209 BF9343_RS05605 2.45 5.2E-14 NADH dehydrogenase 
BF1158 BF9343_RS05365 2.00 2.2E-04 !-glucosidase 
BF3488 BF9343_RS16825 1.87 8.2E-03 phosphonoacetaldehyde hydrolase 
BF0858 BF9343_RS04030 1.68 4.2E-02 MFS transporter 
BF1210 BF9343_RS05610 1.61 2.0E-06 alkyl hydroperoxide reductase 
BF1470 BF9343_RS06775 1.58 4.0E-02 DNA primase 
BF3147 BF9343_RS15100 1.49 4.8E-04 LacI family transcriptional regulator 
- BF9343_RS21640 1.26 8.5E-05 hypothetical protein 
BF3631 BF9343_RS17525 1.19 1.4E-04 30S ribosomal protein S18 
BF0911 BF9343_RS04290 1.18 2.3E-02 cystathionine beta-lyase 
BF1425 BF9343_RS06580 1.17 1.9E-03 membrane protein 
BF3146 BF9343_RS15095 1.16 6.3E-04 SusC/RagA family TonB-linked outer membrane 
protein 
BF3808 BF9343_RS18420 1.07 2.8E-03 carbamoyl phosphate synthase large subunit 
BF3620 BF9343_RS17465 0.97 1.0E-02 4-!-glucanotransferase 
BF1353 BF9343_RS06265 0.96 1.2E-02 iron transporter FeoB 
BF3630 BF9343_RS17520 0.91 9.8E-03 50S ribosomal protein L9 
BF0134 BF9343_RS00595 0.90 2.0E-02 DEAD/DEAH box helicase 
BF4007 BF9343_RS19435 0.87 1.8E-02 30S ribosomal protein S12 
BF3787 BF9343_RS18310 0.83 2.3E-02 50S ribosomal protein L13 
BF2510 BF9343_RS11925 0.83 1.6E-02 50S ribosomal protein L28 
BF0423 BF9343_RS01970 0.79 3.7E-02 phosphate acetyltransferase 
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BF4022 BF9343_RS19510 0.77 3.8E-02 hypothetical protein 
BF0241 BF9343_RS01105 0.76 4.0E-02 phosphoglycerate mutase 
BF2581 BF9343_RS12325 0.76 3.0E-02 elongation factor 4 
tRNA 
BFt59 BF9343_RS19130 1.85 4.8E-04 tRNA-Ala 
BFt60 BF9343_RS19135 1.83 8.6E-04 tRNA-Ile 
BFt37 BF9343_RS12175 1.80 2.1E-09 tRNA-Leu 
BFt72 BF9343_RS21010 1.79 1.8E-04 tRNA-Ala 
BFt38 BF9343_RS12180 1.77 9.7E-09 tRNA-Gly 
BFt30 BF9343_RS11815 1.67 9.1E-03 tRNA-Arg 
BFt56 BF9343_RS18890 1.67 7.2E-04 tRNA-Ala 
BFt33 BF9343_RS12155 1.63 2.8E-07 tRNA-Gly 
BFt36 BF9343_RS12170 1.63 2.5E-08 tRNA-Leu 
BFt06 BF9343_RS02250 1.63 2.0E-06 tRNA-Pro 
BFt07 BF9343_RS02255 1.62 1.2E-05 tRNA-Phe 
BFt51 BF9343_RS18075 1.62 8.3E-04 tRNA-Ala 
BFt39 BF9343_RS13155 1.62 1.4E-03 tRNA-Ala 
BFt73 BF9343_RS21015 1.54 2.3E-02 tRNA-Ile 
BFt13 BF9343_RS04120 1.54 1.6E-06 tRNA-Tyr 
BFt29 BF9343_RS11810 1.52 2.4E-02 tRNA-Arg 
BFt45 BF9343_RS15740 1.50 3.2E-03 tRNA-Ala 
BFt12 BF9343_RS04115 1.50 3.2E-06 tRNA-Gly 
BFt31 BF9343_RS11820 1.45 3.4E-02 tRNA-Arg 
BFt34 BF9343_RS12160 1.41 6.1E-07 tRNA-Leu 
BFt46 BF9343_RS15745 1.41 4.8E-02 tRNA-Ile 
BFt41 BF9343_RS13845 1.35 2.3E-04 tRNA-Asp 
BFt35 BF9343_RS12165 1.32 1.5E-05 tRNA-Gly 
BFt42 BF9343_RS13850 1.28 1.0E-03 tRNA-Asp 
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BFt63 BF9343_RS19520 0.96 1.7E-02 tRNA-Gly 
BFt64 BF9343_RS19525 0.95 1.2E-02 tRNA-Tyr 
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Supplementary Figure 3b | Fold change and adjusted p-value (FDR) of genes most 
down-regulated in tissue compared to lumen. 
old locus 
tag 
new locus tag log2 
(fold 
change) 
FDR Product Name 
BF1252 BF9343_RS05815 -3.16 8.2E-11 DNA methyltransferase 
BF0737 BF9343_RS03450 -2.24 3.1E-04 Polysaccharide G (PSG) flippase 
BF0313 BF9343_RS01440 -2.22 2.5E-04 hypothetical protein 
BF1230 BF9343_RS05705 -2.19 1.2E-04 hypothetical protein 
BF1525 BF9343_RS07025 -2.18 2.4E-07 hypothetical protein 
BF0611 BF9343_RS02855 -2.17 6.2E-06 amino-terminal protease 
BF0739 BF9343_RS03460 -2.16 4.8E-04 hypothetical protein 
BF0738 BF9343_RS03455 -2.06 2.3E-04 glycosyltransferase 
BF2177 BF9343_RS10220 -2.00 1.5E-03 hypothetical protein 
BF2917 BF9343_RS13960 -1.96 1.7E-04 hypothetical protein 
BF3379 BF9343_RS16290 -1.93 9.7E-09 histone H1 
BF3311 BF9343_RS15970 -1.91 2.3E-02 cupin 
BF2442 BF9343_RS11570 -1.88 6.7E-05 hypothetical protein 
BF4220 BF9343_RS20550 -1.83 2.4E-06 DNA-binding protein HU-beta 
BF1509 BF9343_RS06955 -1.81 6.3E-04 hypothetical protein 
BF3026 BF9343_RS14490 -1.80 1.4E-02 phosphohydrolase 
pBF 
9343.09 
BF9343_RS21360 -1.79 9.1E-03 hypothetical protein 
BF0854 BF9343_RS04010 -1.78 2.0E-03 hypothetical protein 
BF2910 BF9343_RS13935 -1.73 1.4E-02 DNA-directed RNA polymerase sigma-70 
factor 
BF0975 BF9343_RS04600 -1.71 1.6E-02 DNA-directed RNA polymerase sigma-70 
factor 
- BF9343_RS05700 -1.65 2.0E-02 conjugal transfer protein 
BF0741 BF9343_RS03470 -1.59 1.6E-02 hypothetical protein 
BF0824 BF9343_RS03860 -1.59 2.3E-02 hypothetical protein 
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pBF 
9343.20c 
BF9343_RS21415 -1.55 8.2E-03 hypothetical protein 
BF0742 BF9343_RS03475 -1.54 4.4E-03 capsular polysaccharide-like protein 
BF3140 BF9343_RS15065 -1.51 6.2E-06 50S ribosomal protein L31 type B 
BF0615 BF9343_RS02870 -1.48 4.8E-04 hypothetical protein 
BF0712 BF9343_RS03330 -1.48 2.4E-02 hypothetical protein 
BF3883 BF9343_RS18770 -1.41 4.3E-02 ubiquitin 
BF0547 BF9343_RS02550 -1.39 1.5E-02 hypothetical protein 
BF1666 BF9343_RS07680 -1.31 1.8E-04 membrane protein 
BF2347 BF9343_RS11095 -1.25 2.3E-02 hypothetical protein 
BF2646 BF9343_RS12645 -1.21 2.3E-02 heat-shock protein 
pBF 
9343.16 
BF9343_RS21395 -1.21 2.3E-02 hypothetical protein 
BF1167 BF9343_RS05410 -1.20 6.5E-04 preprotein translocase subunit YajC 
BF0746 BF9343_RS03495 -1.13 5.8E-03 transposase 
BF4200 BF9343_RS20455 -1.12 9.0E-03 glycosyl transferase family 1 
BF1696 BF9343_RS07830 -1.09 2.3E-02 50S ribosomal protein L35 
BF1168 BF9343_RS05415 -1.02 5.1E-03 hypothetical protein 
BF2361 BF9343_RS11155 -1.00 1.8E-02 RNA-binding protein 
BF3822 BF9343_RS18490 -0.97 2.3E-02 tight junction protein ZO-3 
BF3824 BF9343_RS18500 -0.97 1.2E-02 hypothetical protein 
BF0981 BF9343_RS04630 -0.95 2.0E-02 hypothetical protein 
BF1954 BF9343_RS09125 -0.95 4.0E-03 RNA polymerase sigma factor 
BF0325 BF9343_RS01505 -0.94 4.5E-02 hypothetical protein 
BF1667 BF9343_RS07685 -0.88 3.3E-02 hypothetical protein 
BF0614 BF9343_RS02865 -0.84 3.8E-02 glycosyl transferase family A 
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Supplementary Table 4a: Significantly enriched functional domains in the 68 genes 
differentially expressed in mucus compared to lumen. 
Pfam functional 
domain 
adjusted p-
value (FDR) 
# differentially expressed genes 
containing the functional 
domain  
# total genes in the genome 
containing the functional 
domain 
Glycosyl transferases 
group 1 
0.004 3 28 
Bacterial DNA-
binding protein 
0.0059 2 16 
GTB 0.0242 3 51 
 
Supplementary Table 4b: Significantly enriched functional domains in the 99 genes 
differentially expressed in tissue compared to lumen. 
Pfam functional domain adjusted p-
value (FDR) 
# differentially expressed 
genes with the functional 
domain  
# total genes in the 
genome with the 
functional domain 
Elongation factor Tu domain 2 0.0028 2 7 
50S ribosome-binding 
GTPase 
0.0036 3 16 
Elongation factor Tu GTP 
binding domain 
0.0069 2 10 
Glycosyl transferases group 1 0.0185 3 28 
Type I phosphodiesterase / 
nucleotide pyrophosphatase 
0.0324 2 19 
  
Supplementary Table 4c: Significantly enriched functional domains in the 130 genes 
differentially expressed in both mucus and tissue, as compared to lumen (FDR < 0.05). 
Pfam functional domain adjusted p-
value (FDR) 
# differentially expressed 
genes with the functional 
domain  
# total genes in the 
genome with the 
functional domain 
 Elongation factor Tu domain 
2 
0.0045 2 7 
 50S ribosome-binding 
GTPase 
0.0066 3 16 
 Sigma-70 region 2 0.0106 5 43 
 Elongation factor Tu GTP 
binding domain 
0.0106 2 10 
 Sigma-70, region 4 0.0115 5 44 
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 ECF sigma factor 0.0128 2 11 
 Glycosyl transferases group 1 0.0287 3 28 
 Bacterial DNA-binding 
protein 
0.0294 2 16 
 Bacterial regulatory proteins, 
luxR family 
0.0396 2 18 
 Type I phosphodiesterase / 
nucleotide pyrophosphatase 
0.0453 2 19 
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METHODS 
Bacteria strains and media 
B. fragilis NCTC9343 was cultured in Brain Heart Infusion (BD) with 5 µg/ml hemin 
(Frontier Scientific) and 5 µg/ml vitamin K1 (Sigma) or a defined minimal media42,43 in an 
80% nitrogen, 10% carbon dioxide, and 10% hydrogen atmosphere. For growth in mouse 
mucus, crude mucus was isolated as described below (Separation of colon lumen, mucus, 
and tissue) from the entire colon of germ-free mice into defined minimal media (mucus from 
one whole colon homogenized in 5 ml of final media). Where appropriate, 200 µg/ml 
gentamicin, 10 µg/ml erythromycin, 2 µg/ml tetracycline, or 10 µg/ml chloramphenicol were 
used in selective media. For competitive colonization and horizontal transmission, marker 
plasmids pFD340-Chlor (providing resistance to erythromycin and chloramphenicol) or 
pFD340-Tet (providing resistance to erythromycin and tetracycline) were used to distinguish 
two strains, as before23. In-frame deletions in BF3086 (1305 bp deleted) and BF3134 (1686 
bp deleted) were made using allelic exchange with the pNJR6 suicide vector as previously 
described23. 
 
Mice and colonization experiments 
All animal experiments were performed in accordance with guidelines in the NIH Guide for 
the Care and Use of Animals and protocols approved by the Caltech Institutional Animal 
Care and Use Committee. Swiss Webster mice from Taconic Farms were c-section re-
derived germ-free and bred in flexible film isolators. For most experiments, germ-free mice 
were transferred at 6-8 weeks of age to sterile micro-isolator cages with autoclaved food 
(LabDiet 5010) and water. Mice were mono-colonized by a single gavage with 108 CFU of 
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B. fragilis in 100 µl of HBSS with 1.5% sodium bicarbonate (or a 1:1 mix of 108 CFU each 
of two strains, for competitive colonization). Mice were maintained mono-colonized for 4 
weeks prior to subsequent experimentation. Colonization was monitored in fresh fecal 
samples which were weighed, mashed, and vortexed in 1 ml BHI and diluted for plating 
CFU. For mucosal CFU plating, mucus was isolated as described below (Separation of colon 
lumen, mucus, and tissue). For competitive colonization and horizontal transmission assays, 
water was supplemented with 100 µg/ml gentamicin (Bacteroides are naturally resistant) and 
10 µg/ml erythromycin (to select for marker plasmids). Horizontal transmission was assayed 
as previously23, by co-housing mice for 4 hours in a fresh sterile cage and then separating 
into single-housing in fresh sterile cages. 
 
Separation of colon lumen, mucus, and tissue 
Animals were sacrificed one at a time and samples were quickly processed through the bead-
beating lysis step (< 10 minutes from sacrifice to lysis). Lysed samples were kept at 4 C until 
all samples were collected. First, the proximal colon was dissected. A 1 cm segment of the 
proximal (ascending) colon, starting at the cecal junction, was taken for sampling. The 
segment was opened longitudinally and ~100 mg of lumen content was collected for the 
“lumen” sample. The rest of the lumen content was removed with forceps. The tissue was 
washed by vigorously shaking with forceps in a dish of HBSS for 20 seconds (changing 
forceps grip 3 times during the process). The washed tissue was carefully observed to ensure 
no lumen content remained. Tissue was dabbed in a dry sterile petri dish to remove excess 
buffer. Mucus was scraped from the surface of the tissue using a sterile plastic 1.8 cm cell 
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scraper (BD Falcon), collected as the “mucus” sample. The remaining tissue was collected 
as the “tissue” sample. 
 
RNA purification 
All samples were subjected to the same RNA preparation protocol, which was the only 
method we found to reproducibly provide high-quality and high-yield RNA from lumen, 
mucus, and tissue. Samples were immediately lysed by bead-beating for 1 minute in 2 ml 
lysing matrix B tubes (MP Biomedicals) with 500 µl buffer (0.2 M NaCl and 20 mM EDTA), 
210 µl 20% SDS (Ambion AM9820), and 500 µl phenol, chloroform, isoamyl alcohol 
mixture (Ambion AM9720). After centrifugation at 13,000 rpm for 3 minutes at 4 C, the 
aqueous phase was added to a new microcentrifuge tube with 500 µl of the phenol, 
chloroform, isoamyl alcohol mixture, and mixed by inversion. The centrifugation and 
isolation of aqueous phase was repeated, yielding about 300 µl. Next, 30 µl of 3 M sodium 
acetate (Ambion AM9740) and 300 µl of -20 C 100% ethanol was mixed in by inversion. 
Samples were left on ice for 20 minutes, then centrifuged at 13,000 rpm for 20 minutes at 4 
C. The supernatant was decanted and 500 µl of -20 C 70% ethanol was added and vortexed 
before centrifuging at 13,000 rpm for 5 minutes at 4 C. The supernatant was decanted and 
the tubes were inverted and air-dried for 5 minutes after wiping the lips of tubes dry on 
Kimwipes. 100 µl of water was added to the dried pellets, which were then frozen at -20 C. 
The next day, samples were thawed and 350 µl RLT buffer (Qiagen) with 1% 2-
mercaptoethanol was added. Tubes were vortexed for 20 minutes, at which point the pellets 
were completely dissolved. The samples were then loaded on Qiagen RNeasy mini columns 
and purified according to the manufacturer’s instructions. Nucleic acids were eluted in 50 µl 
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of water and quantified using a NanoDrop. Up to 10 µg of this was taken into a 60 µl DNase 
reaction with 4 µl Turbo DNase (Ambion AM2238) at 37 C for an hour. 40 µl of water and 
350 µl buffer RLT were added and the samples were loaded onto a second Qiagen RNeasy 
mini column. The second column purification was performed according to the 
manufacturer’s instructions including the Qiagen on-column DNase digest. The final total 
RNA was eluted in 50 µl water. 
 
Preparation of whole-transcriptome fragment libraries (pond) for hybrid selection  
The isolated RNA was first quantified and qualified by Qubit and Agilent Bioanalyzer. The 
RNA was then fragmented by FastAP (Thermo Scientific) and linked to barcoded adapters. 
The fragmented and barcoded RNA was pooled to perform ribosomal RNA depletion using 
Ribo-Zero Magnetic Gold Epidemiology Kit (Epicentre/Illumina). The cDNA was generated 
from the RNA through template-switching RT-PCR. After exonuclease I treatment and PCR 
enrichment, the RNA was used for hybrid selection. 
 
Hybrid selection probes (bait) construction 
Whole genome bait (WGB) was generated at the Broad Institute. For input, 3 µg of B. fragilis 
NCTC 9343 DNA was sheared for 4 minutes on a Covaris E210 instrument set to duty cycle 
5, intensity 5 and 200 cycles per burst. The mode of the resulting fragment size distribution 
was 250 bp. End repair, addition of a 3'-A, adaptor ligation and reaction clean-up followed 
the Illumina's genomic DNA sample preparation kit protocol, except that the adapter 
consisted of oligonucleotides 5'-TGTAACATCACAGCATCACCGCCATCAGTCxT-3' 
('x' refers to an exonuclease I-resistant phosphorothioate linkage) and 5'-
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[PHOS]GACTGATGGCGCACTACGACACTACAATGT-3'. The ligation products were 
cleaned up (Qiagen), amplified by 8 to 12 cycles of PCR on an ABI GeneAmp 9700 
thermocycler in Phusion High-Fidelity PCR master mix with HF buffer (NEB Ipswich, 
Massachusetts, United States) using PCR forward primer 5'-
CGCTCAGCGGCCGCAGCATCACCGCCATCAGT-3' and reverse primer 5'-
CGCTCAGCGGCCGCGTCGTAGTGCGCCATCAGT-3' (ABI Carlsbad, California, 
United States). Initial denaturation was 30 s at 98°C. Each cycle was 10 s at 98°C, 30 s at 
50°C and 30 s at 68°C. PCR products were size-selected on a 4% NuSieve 3:1 agarose gel 
followed by QIAquick gel extraction. To add a T7 promoter, size-selected PCR products 
were re-amplified as above using the forward primer 5'-
GGATTCTAATACGACTCACTATACGCTCAGCGGCCGCAGCATCACCGCCATCA
GT-3'. Qiagen-purified PCR product was used as template for whole genome biotinylated 
RNA bait preparation with the MEGAshortscript T7 kit (Ambion)19,20. 
 
Hybrid selection 
Using the designed baits, hybridization was conducted at 65°C for 66 h with 2 µg of 'pond' 
libraries carrying standard or indexed Illumina paired-end adapter sequences and 500 ng of 
bait in a volume of 30 µl. After hybridization, captured DNA was pulled down using 
streptavidin Dynabeads (Invitrogen Carlsbad, California, United States). Beads were washed 
once at room temperature for 15 minutes with 0.5 ml 1 × SSC/0.1% SDS, followed by three 
10-minute washes at 65°C with 0.5 ml pre-warmed 0.1 × SSC/0.1% SDS, re-suspending the 
beads once at each washing step. Hybrid-selected DNA was eluted with 50 µl 0.1 M NaOH. 
After 10 minutes at room temperature, the beads were pulled down, the supernatant 
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transferred to a tube containing 70 µl of 1 M Tris-HCl, pH 7.5, and the neutralized DNA 
desalted and concentrated on a QIAquick MinElute column and eluted in 20 µl. 
 
Sequencing 
Each sample was sequenced on Illumina HiSeq2500 at the Broad Institute to produce 101-
bp paired-end reads. Sequence data have been deposited in the NCBI Short Read Archive 
under a project accession number, PRJNA438372. 
 
RNA-seq read processing and mapping 
Identifiers for all RNA-seq experiments are listed in Supplementary Table 1. The RNA-seq 
reads were trimmed with a Phred quality score cut-off of 20 by the program 
fastq_quality_trimmer from the FASTX toolkit, version 0.0.13 
(http://hannonlab.cshl.edu/fastx_toolkit/). Reads shorter than 20$bp after adaptor- and 
poly(A)-trimming were discarded before mapping. Trimmed RNA-seq reads were aligned 
to the B. fragilis NCTC 9343 genome (NC_003228.3) and the mouse genome (genome build 
GRCm38.p4) in parallel. RNA-seq read mapping to the bacterial and mouse genome were 
performed by Bowtie244 and STAR45, respectively.  The mapping results were used to 
calculate read counts over each gene of the bacterial and mouse genomes by bedtools46 and 
HTseq47, respectively.  We also calculated read coverage and transcripts per million (TPM) 
for each bacterial gene for examining the distribution of bacterial gene expression.  
 
Differential gene expression analysis 
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Read counts for each bacterial gene were used to analyze differential gene expression using 
the edgeR package48. Bacterial genes with more than 10 uniquely mapped reads in each of 
three replicates were considered to be detected and were retained for the differential gene 
expression analysis. Genes with an adjusted p-value$<$0.05 in the edgeR analysis were 
considered differentially expressed. 
 
Functional enrichment and other statistical analysis 
We annotated the bacterial genes with Pfam24 using the Broad Institute’s prokaryotic 
annotation pipeline49. To assess functional enrichment of differentially expressed genes, we 
calculated statistical significance using the hypergeometric function with adjustment for 
multiple hypothesis testing. Adjusted p-values$<$0.05 were considered enriched. We 
calculated Pearson correlation coefficients to determine if the expression of genes (in TPM) 
were comparable between two samples. We used the Wilcoxon signed-rank test to compare 
the expression of a gene family in two different samples.  p-values$<$0.05 were considered 
significant. 
 
Comparative genomics and motif analysis of 92 Bacterioides and Parabacteroides 
genomes  
Using a comparative analysis of 92 diverse genome sequences related to B. fragilis 50, ,which 
included 23 Bacteroides and 5 Parabacteroides species, we identified 43 BF3134 orthologs 
in 43 strains  and 117 BF3086 orthologs in 83 strains. We constructed multiple alignments 
of the nucleotide sequences of these groups of orthologs for BF3086 and BF3134, which we 
used to calculate pairwise sequence identities to measure conservation levels. We searched 
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the upstream regions of BF3086 and BF3134 in B. fragilis NCTC 9343 for conserved motifs, 
or potential binding sites for transcription factors, using GLAM251 from the MEME suite52. 
We further examined the presence and conservation of this potential regulatory motif using 
GLAM2Scan51 on our set of  92 diverse Bacteroides and Parabacteroides genome sequences 
(Supplementary Figure S3)50. Presence of the motif was defined by having 2 or less 
mismatches. Of the 16 B. fragilis genomes, we used multiple sequence alignments to confirm 
that the 3 divergent B. fragilis are missing the predicted motif (Supplementary Figure S4 and 
S5). Excluding three same-patient samples, the B. fragilis genomes containing the motif had 
a pairwise average nucleotide identity (ANI) value of 98%, indicating that these strains are 
members of the same species, but not clonally related. In contrast, pairwise ANI values 
between B. fragilis strains with and without the motif averaged 86%, below the threshold 
commonly used to describe species49,53. 
 
Epithelial cell adherence assay 
The stable intestinal epithelial cell line Caco-2 was maintained in high glucose DMEM with 
4 mM L-glutamine, 4.5 g / L glucose (HyClone), supplemented with 10% fetal bovine serum 
(FBS) (Gibco), and penicillin-streptomycin solution (Corning). 25,000 cells were seeded in 
flat 96-well plates and grown for ten days past confluence (~13 days after seeding) to allow 
production of mucus. One day prior to the adherence assay, the media was changed to high-
glucose DMEM without antibiotics or FBS. Bacteria from fresh cultures in BHI were 
pelleted and re-suspended in high-glucose DMEM without antibiotics or FBS. Epithelial 
cells were washed once with warm HBSS and then incubated with 106 CFU of bacteria for 
2 or 4 hours at 37 C in an anaerobic atmosphere of 80% nitrogen, 10% carbon dioxide, and 
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10% hydrogen. Wells were washed twice with 200 µl warm HBSS to remove unbound 
bacteria, and then trypsinized with 50 µl of 0.05% trypsin in HBSS (Corning) for 20 minutes 
at 37 C to disassociate epithelial cells. Cells were vigorously resuspended with 50 µl BHI 
added to the trypsin before dilution plating for CFU. Fraction bound was calculated as the 
output CFU / input CFU. 
 
DNBS colitis 
Mice were mono-colonized at 3 weeks of age and colitis was induced 4 weeks later. Mice 
were anesthetized using isofluorane and 5% DNBS in 50% ethanol (or 50% ethanol only) 
was administered rectally through a 3.5F catheter (Instech Solomon) inserted 4 cm into the 
colon. Mice were subsequently kept upside-down for 1 minute to prevent leakage. Mice were 
weighed every 24 hours and sacrificed at 72 hours post-induction. The whole colon was 
dissected, fixed in 10% buffered formalin, paraffin embedded, sectioned, and then stained 
with hematoxylin and eosin (HE). 
 
Isolation of mesenteric lymph node lymphocytes and flow cytometry 
Mesenteric lymph nodes (MLN) were isolated and processed by dissociating tissues through 
a 70 µm cell strainer (BD Falcon) to generate single cell suspensions. Cells were washed in 
ice cold PBS. For flow cytometry analysis, cells were labelled with the LIVE/DEAD fixable 
violet dead cell stain kit (Life Technologies), with empirically titrated concentration of PE-
Cy7-conjugated anti-mouse CD4 (RM4-5, eBioscience). For intracellular staining, cells were 
fixed and permeabilized with the Foxp3/Transcription factor buffer kit (eBioscience), 
followed by staining with the following antibodies: FITC-conjugated anti-mouse IFNγ 
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(XMG1.2, eBioscience), PE-conjugated anti-mouse IL-10 (JES5-16E3, eBioscience), 
PerCP-Cy5.5 anti-mouse IL-17A (eBio17B7, eBioscience), and APC-conjugated anti-mouse 
Foxp3 (FJK16s, eBioscience). Cell acquisition was performed on a Miltenyi MACSQuant 
(Miltenyi), and data was analyzed using FlowJo software suite (TreeStar). 
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THESIS CONCLUSION 
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“The plagues fade, but microbes remain; and vestiges of the memory of the formidable ones 
cling to those that live innocently, even beneficently, on man.” 
-Theodor Rosebury, 1969, Life on Man 
 
Almost a century before Darwin’s “Origin of Species,” Antonie van Leeuwenhoek turned 
his microscope toward his own body and discovered that we do not live alone. His letters 
describe a diverse oral and gut microbiome during health, which appeared to change during 
disease. Despite these early indicators of its importance, the indigenous microbiome of 
animals was largely an afterthought through the 20th century. In the context of association 
with animals, bacteria were studied as pathogens. 
 
The development of anaerobic culture methods and gnotobiotics facilitated a revolution in 
microbiome research in the 1960’s. René Dubos was by then an eminent bacteriologist at the 
Rockefeller University, known for being the first to deliberately discover an antibiotic. 
Inspired by his observations about the importance of nutrition in immunity, he turned his 
laboratory to a reductionist study of the mouse intestinal microbiome. In a remarkable series 
of papers, Russell Schaedler and Dubos described the sequential development of the gut 
microbial community in pups1, its dependence on diet2, spatial differences along the length 
of the gut2, and a specific mucosal community composition2. Furthermore, they established 
the experimental paradigm of colonizing germ-free mice with individual species or defined 
communities3. 
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Dubos and colleagues understood that studying feces was a poor approximation of what was 
happening inside the gut. Dwayne Savage, another member of Dubos’s group, applied 
imaging techniques to the study of the mucosal microbiome4, later discovering segmented 
filamentous bacteria5 and crypt-associated bacteria6. Savage championed the idea that the 
intestinal surface was heavily colonized during health, providing protection from pathogen 
colonization7. Decades later, segmented filamentous bacteria would become an important 
model for interactions with immunoglobulin A (IgA)8 and effects of the microbiome on T 
cell development9. Despite their age and limited impact at the time, the studies from Dubos, 
Schaedler, and Savage provide a still-relevant foundation for molecular symbiosis research.  
 
Armed with genetics and molecular biology in addition to traditional techniques, this thesis 
explores the same question that inspired Dubos: how do bacteria colonize the gut during 
health? The chapters contain several examples of mechanisms of mucosal colonization and 
the importance of gut biogeography to the form and function of the microbiome. They 
provide support for the hypothesis that the mucus serves as a privileged niche and reservoir 
for bacteria. This microbiome reservoir hypothesis was proposed as a function of the human 
appendix in 2007 by Randall Bollinger and William Parker at Duke University10. Four years 
earlier, the same group hypothesized that antibodies (IgA) could enhance mucosal 
colonization11. The reductionist approach described in this thesis, using colonization 
experiments in gnotobiotic mice, provides mechanistic support for these high-level concepts. 
 
The study of mucosal colonization by indigenous bacteria necessitates an immunological 
awareness. The science of immunology has been historically framed by pathogenesis, though 
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the immune system itself evolved in the context of symbiosis. Obligate microbial symbionts 
and the animal gut are bound together by co-evolution. The mutualistic relationship between 
Bacteroides fragilis and the mammalian immune system should therefore not come as a 
surprise. But the manner in which this symbiosis manifests is surprising in that there are 
many parallels to pathogenesis. Bacterial capsules have been well-described as virulence 
factors, allowing pathogens to cloak themselves to avoid immune attacks, such as antibody 
recognition. This paradigm is reversed for B. fragilis, which uses a capsule to attract antibody 
binding. Here, antibodies don’t act as weapons, but as anchors for mucosal symbiosis. The 
insults that most bacteria would struggle to endure in the mucus do not appear to perturb B. 
fragilis, which lives and thrives on the intestinal surface. The effect of mucosal colonization 
on the host is also unintuitive from a pathogenesis-framed immunological perspective. 
Mucosal B. fragilis provides a protective anti-inflammatory signal. 
 
To view the immune system in its entirety as a barrier preventing microbial colonization is 
to miss half of the story. The immune system must exclude threatening microbes, but it 
allows long-term colonization of the surface of tissues all over the body. It might be tempting 
to interpret the tolerance of the gut microbiome as the immune system recognizing these 
bacteria as “self.” But the data here indicates otherwise: the immune system recognizes 
indigenous mucosal microbiota as allies. 
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